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The journey is never over. Only travellers come to an end. But even then, they 
can prolong their voyage in their memories, in recollections, in stories. The 
end of one journey is simply the start of another. You have to see what you 
missed the first time, see again what you already saw, see in springtime what 
you saw in summer, in daylight what you saw at night, see the sun shining 
where you saw the rain falling, see the crops growing, the fruit ripen, the 
stone which has moved, the shadow that was not there before. You have to 
start the journey anew. Always. The traveller sets out once more. 
        José Saramago  
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LAY SUMMARY  
 
Blood cells are responsible for many primary functions in the human body, such as 
fighting external pathogens (white cells) and providing oxygen to tissues (red cells). 
Constant supplies of blood cells are ensured by blood (hematopoietic) stem cells 
(HSCs), which are present in the bone marrow during adult life. When required, these 
HSCs undergo serial divisions to become all mature blood cells.  
Sometimes, HSCs are subjected to uncontrolled divisions that change their behaviour 
and generate blood cancer cells. Unfortunately, current therapies cannot eliminate 
blood cancer cells. One approach to restore a normal blood system is to replace patient 
cancer cells with new healthy HSCs that have been generated in the laboratory. This 
can be achieved only if we understand more about healthy HSCs, such as how and 
where they are generated. HSCs are made by continuous changes in specific cells 
during the embryonic stage of development. During this stage, we discovered an 
important protein, Gpr56, that is required for HSC generation. However, the reasons 
why Gpr56 is important for HSCs remains unknown.  
To understand the role of Gpr56 in HSC development, we investigated what happens 
to HSC behaviour when the quantity of Gpr56 is altered. When the amount of Gpr56 
is increased, we found that more HSCs were generated, whilst in the absence of Gpr56, 
we found that HSCs preferentially differentiate into white blood cells. We discovered 
that another similar protein, Gpr97 appears to compensate for the lack of Gpr56.  When 
both proteins are absent, fewer HSCs are generated. 
In summary, this thesis demonstrates that Gpr56 is a key protein in HSC development 
and can be replaced by the very similar Gpr97 protein. Further work to advance 
understanding of its mechanistic role is warranted and may provide useful insights in 
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ABSTRACT  
 
Haematopoietic stem cells (HSCs) can differentiate into all blood cell types, making 
HSC transplantation a promising treatment for many blood-related disorders. 
Allogenic heathy HSCs can be transplanted into patients, although this approach is 
limited by availability and compatibility of the donor. Moreover, there are no protocols 
available to generate transplantable HSCs from pluripotent stem cells (PSC), or expand 
HSCs ex vivo, as the molecules involved in HSC ontogeny remain poorly understood. 
Embryonically, HSCs derive from a subset of aortic endothelial cells that undergo 
endothelial-to-hematopoietic transition to become HSCs. During this dynamic 
process, Gpr56 is the most upregulated receptor in emerging HSCs. The Gpr56 protein 
is a cell-surface receptor that is likely involved in the regulation of HSC function. 
However, its role in mammalian haematopoiesis remains unknown.  
In this study, we examine the function of Gpr56 during in vivo and in vitro HSC 
development. To explore the effect of Gpr56 loss-of-function, we characterize the 
functional role of mouse embryonic stem cell (ESC) derived hematopoietic stem and 
progenitor cells (HSPCs) and in vivo mouse HSCs that lack Gpr56. Gpr56-deficient 
HSPCs have a differentiation bias towards myeloid cells and the upregulation of 
another GPCR, Gpr97 appeared to compensate for Gpr56 deletion. The simultaneous 
deletion of Gpr56 and Gpr97 severely impaired the production of HSPCs, suggesting 
that both GPCRs are required in vitro for HSPC generation. Conversely, Gpr56 
overexpression during human in vitro PSC differentiation resulted in an important 
HSPC expansion. In summary, these data demonstrate that the lack of Gpr56 alters the 
HSPC differentiation output, while its overexpression enhances human in vitro HSPCs 
generation. This work represents the most comprehensive and current study of Gpr56 
in mammalian haematopoiesis and these findings will improve novel strategies to 
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1 INTRODUCTION 
1.1 The discovery of haematopoietic stem cells  
The discovery of hematopoietic stem cells (HSCs) occurred with the unfortunate 
advent of atomic weapons during the second world war. In the first half of the 20th 
century the scientific community focused its interest on how to protect normal tissues 
from damages caused by ionizing radiation, attesting that the bone marrow (BM) is 
one of the most radio sensitive tissues. In mice, scientists found that the injection of 
whole normal adult bone marrow was able to protect lethally irradiated recipients. 
Surprisingly, the recipient mice entirely restored a healthy hematopoietic system, 
suggesting the existence of multipotent cells within the BM cell population: the HSCs. 
The unknown entity of these cells prompted scientists to seek HSCs and characterize 
their biological features (Jacobson, Simmons et al. 1951, Lorenz, Uphoff et al. 1951, 
Ford, Hamerton et al. 1956). The first step was to quantitatively characterize HSCs. 
This aim was addressed performing a limiting diluting transplantation assay (LDA) 
(McCulloch and Till 1960). This experimental assay estimated the frequency of HSCs 
in the BM by defining the minimal number of BM cells that repopulate the hosts. The 
experiments demonstrated that in the adult BM the HSCs are rare. Interestingly, 10 
days after the BM transplantation into myeloablated mice, some macroscopic cell 
“clusters” appeared on the surface of the host spleens. These cell formations are called 
spleen colony-forming units (CFU-S) and their number was directly related to the 
number of transplanted HSCs (Till and Mc 1961). In addition, cytological analyses on 
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CFU-S composition revealed novel HSC qualitative features. Each CFU-S cluster 
consisted of a mixture of lymphoid and myeloid hematopoietic differentiated cells, 
which derived from a single parental clone (Wu, Till et al. 1967). Notably, this ability 
was maintained after serial transplantations, indicating the so called “self-renewal” 
capacity.  
These milestone experiments established two HSC fundamental features: 
differentiation and self-renewal capacities. That means that, when serially 
transplanted into recipients, these rare HSCs hold the potential to clonally differentiate 
in all the mature blood cell types while preserving their initial pool. These 
observations structured the hematopoiesis as a stepwise process where few 
multipotent cells differentiate unidirectionally towards all mature blood cells. 
1.1.1 Hematopoietic hierarchy and heterogeneity  
The presence of HSCs in the BM prompted scientists to develop strategies to isolate 
HSCs and understand the relation with the hematopoietic progeny. Using a 
combination of cell surface markers, pioneer studies employed fluorescent activated 
cell sorting (FACS) to purify HSCs and their progeny (Spangrude, Heimfeld et al. 
1988, Ikuta, Kina et al. 1990, Ikuta and Weissman 1992, Morrison, Wandycz et al. 
1997). Based on the cell surface markers and in vivo functional assays, the HSCs can 
be divided into long term (LT) and short term (ST) HSCs. LT-HSCs possess a 
permanent reconstitution capacity (> 3-4 months), while ST-HSCs repopulate the 
recipients for 8-12 weeks only (Morrison, Wandycz et al. 1997). These ST-HSCs 
differentiate into multipotent progenitors (MPPs), with reduced self-renewal ability 
(Yang, Bryder et al. 2005) and can further differentiate into common myeloid (CMPs) 
and common lymphoid progenitors (CLPs). CMPs have myeloid restricted potential 
and generate erythrocytes, megakaryocytes and granulocytes-macrophage cells. 
Conversely, the CLP progenitors have the capacity to generate all the lymphoid 
mature cells. To describe the connection between HSCs and their progeny, the 
Weissman group established the classical tree-like branch hematopoietic hierarchical 
model (Morrison, Uchida et al. 1995, Kondo, Weissman et al. 1997, Morrison, 
Wandycz et al. 1997, Akashi, Traver et al. 2000, Manz, Miyamoto et al. 2002) (Figure 
1.1). According to this model, HSCs sit on top of hematopoietic hierarchy and 
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differentiate first to multipotent progenitors (MPPs), then towards single lineage 
restricted progenitors (unipotent) and finally, to terminally differentiated mature 
blood cells.  
Although the surface markers define HSCs as a homogenous population, in vivo 
functional analyses revealed that they are heterogeneous. LDA and clonal 
transplantation assays attested the existence of  myeloid-biased, lymphoid-biased and 
balanced BM HSCs (Muller-Sieburg, Cho et al. 2002, Dykstra, Kent et al. 2007). 
Using similar approaches, other groups identified platelets-biased HSCs (Sanjuan-Pla, 
Macaulay et al. 2013) and intermediate (IT) HSCs (Benveniste, Frelin et al. 2010, 
Yamamoto, Morita et al. 2013). The advent of single cell omics and lineage tracing 
approaches confirmed the presence of heterogenous BM HSCs with distinct features. 
The Jacobsen laboratory found platelet-biased HSCs that co-express cKit and the 
platelet/megakaryocyte marker von Willebrand Factor (vWF+) (Carrelha, Meng et al. 
2018). These HSCs can exclusively replenish megakaryocytes-platelets without 
differentiating into hematopoietic intermediates. In another study, Crisan and 
colleagues demonstrated the presence of two genetically distinct subpopulations of 
BM-HSCs that respond differently to BMP signalling: HSC BMP-activated and non-
BMP activated, (Crisan, Kartalaei et al. 2015). The concept of heterogeneity can be 
extended also to the MPPs. MPPs derive from HSCs and are a heterogeneous 
population that consist of MPP1, MPP2, MPP3 and MPP4 (Pietras, Reynaud et al. 
2015). The subpopulations differ for transcriptomic profile, cell cycle activity and 
abundance in the bone marrow (Wilson, Laurenti et al. 2008). MPP1s have molecular 
features closely associated with ST-HSCs, whereas MPP4s is primed to segregate into 
downstream progenitors (Pietras, Reynaud et al. 2015). However, the biological 
mechanisms by which a single HSC differentiates into MPPs is still under 
investigation.  
The origin of HSC heterogeneity is likely to be found at embryonic level (reviewed in 
(Crisan and Dzierzak 2016). During embryonic development there are several 
intrinsic and extrinsic factors that contribute to the onset of definitive HSCs. A better 
knowledge of those molecular signals will be crucial to develop new protocols for in 
vitro generation of bona-fide HSCs to be used as therapy for blood-related diseases. 
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Figure 1.1 Representation of the classic hematopoietic hierarchy  
Hematopoietic stem cells (HSCs) reside on top of the hematopoietic hierarchy. They retain 
the capacity to self-renew and differentiate into committed progenitors which generate fully 
matured blood cells. Along their differentiation, HSCs gradually lose their self-renewal 
capacity, whereas their progeny acquire proliferation capacity. Figure adapted from [Bryder 
et al, 2006] copyright permission, Elsevier. 
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1.2 Hematopoiesis during embryonic development   
 
1.2.1 Early embryonic hematopoiesis 
Adult HSCs reside in the bone marrow (BM) surrounded by different cell types that 
provide a supportive environment to maintain HSCs throughout adult life. These 
definitive adult repopulating HSCs take their origins during embryonic development. 
The first developmental studies to investigate the embryonic origin of blood cells were 
performed on chickens. The concomitant appearance of primitive blood cells and 
vascular cells in the same embryonic compartment raised the idea that hematopoietic 
cells originate embryonically from a common mesodermal precursor: the 
hemangioblast (reviewed by (Choi 1998). 
In the second half of the 60s, Moore and Owen conducted elegant experiments in 
avian and mouse embryos to study the origin of blood cells. The experiments 
performed in mouse embryos demonstrated that the yolk sac (YS) contained 
hematopoietic precursors capable to colonise the spleen and the bone marrow of 
lethally irradiated hosts (Moore and Owen 1965, Moore and Owen 1967, Moore and 
Metcalf 1970). These studies set the first paradigm that hematopoiesis and the 
generation of HSCs initiate in the YS during the embryonic development. It was in 
1975 when a French scientist, Dieterlen-Lièvre, made an important shift in the dogma. 
The generation of YS chimeras in an experimental avian embryo model and the ability 
to morphologically discriminate chicken from quail embryonic cells allowed 
Dieterlen-Lièvre to demonstrate for the first time that HSCs originate from the embryo 
body and not from an external embryonic compartment such as the YS (Dieterlen-
Lievre 1975). The impact of her pioneering work prompted the scientific community 
to re-consider the spatiotemporal origin of embryonic haematopoiesis and ask whether 
the same developmental process might be conserved in other vertebrates and 
particularly in mammalian vertebrates (mouse and human). 
Mammalian hematopoiesis takes place in different embryonic compartments of the 
conceptus following distinct spatial and temporal events (Dzierzak and Speck 2008). 
Similar to chicken embryos, in mice, blood cells originate in the YS from a 
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mesodermal-derived group of cells defined as “hemangioblast” (Murray 1932). At day 
(E)7 of mouse embryonic development, these cells migrate from the primitive streak 
to the YS where they differentiate into endothelial cells (ECs) and blood islands. The 
blood islands are clusters or primitive erythroblasts surrounded by endothelial cells, 
which establish the YS vasculature (Ferkowicz and Yoder 2005, Ueno and Weissman 
2006). The embryonic morphological and molecular similarities between endothelial 
and primitive hematopoietic cells postulated the idea of the hemangioblast as a 
common bipotent ancestor. This bipotent cell shares the expression of common 
surface mesodermal receptors: brachyury and the foetal liver kinase 1 (Flk1). Lack of 
Flk1 resulted in embryonic lethality and impaired production of mesodermal 
intermediates and blood islands (Yamaguchi, Dumont et al. 1993). 
The first wave of hematopoiesis initiates in the YS between E7 and E8.5 of murine 
embryonic development (Figure 1.2) (Dzierzak and Speck 2008). During this first 
wave of de novo hematopoiesis, “primitive” erythrocytes and myeloid progenitors 
(macrophages and megakaryocytes) are produced prior the establishment of the 
circulation, which occurs around E8.25-8.5 (McGrath, Koniski et al. 2003). Primitive 
erythrocytes are nucleated and express an embryonically distinct (H1) globin (Palis, 
Robertson et al. 1999), YS-derived macrophages are thought to mature directly from 
the blood islands (Manwani and Bieker 2008). The end of the first wave overlaps with 
the beginning of the second one. This new wave takes place in the YS from E8.25 and 
it is characterized by de novo production of hematopoietic cells with multipotent 
myeloid and/or lymphoid potentials (Palis, Robertson et al. 1999, Dzierzak and Speck 
2008). This second wave is often called “definitive” as it gives rise to more 
functionally competent progenitors that closely relate to adult blood cells. The most 
abundant haematopoietic progenitor population is represented by the erythroid-
myeloid progenitors (EMPs), which are generated from E8.25 to E10 and express the  
tyrosine receptor kinase (cKit or CD117), CD41 and CD16/32 (McGrath, Frame et 
al. 2015) (Figure 1.2). Moreover, a rare population of B-cells (B1a) and T cell 
lymphoid progenitors with low multilineage repopulation activity arise just after the 
onset of EMPs (Yoshimoto, Porayette et al. 2012).  
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1.2.2 The onset of mouse HSC development  
The third wave of hematopoietic generation is also known as definitive and begins 
with the generation of the first adult-repopulating HSCs, which represent the basis of 
the hematopoietic system throughout adult life. In mice, the first adult-type HSC arises 
at E10.5 from an intraembryonic region called aorta gonad mesonephros (AGM) 
(Medvinsky and Dzierzak 1996) (Figure 1.2). Cell tracing experiments performed in 
mouse embryos showed that HSCs directly originate from a subset of vascular 
endothelial cells (ECs) lining the ventral wall of the dorsal aorta. (Zovein, Hofmann 
et al. 2008). These ECs undergo a trans-differentiation process  described as 
endothelial-to-hematopoietic cell transition (EHT) (Jaffredo, Bollerot et al. 2005, 
Kissa and Herbomel 2010). The EHT is a well conserved process that has been widely 
investigated in different organisms (Kissa and Herbomel 2010). During the transition, 
few cells bulge from the endothelium into the lumen of the aorta to form the intra-
aortic hematopoietic cells that are found in clusters (IAHCs).  
Three-dimensional imaging analysis of whole mouse embryo demonstrated that 
hematopoietic clusters can be detected in the major embryonic arteries (Yokomizo 
and Dzierzak 2010). In the embryonic aorta, the total number of IAHCs peaks at E10.5 
(~600)  among which only few HSCs are generated (Kumaravelu, Hook et al. 2002), 
whilst the rest are HPCs. Each IAHC is made of 2 to 20 cells that are defined to be 
cKit+CD31+SSEA1. Immunostaining assays performed on those cells revealed the 
presence of 3 different cell populations within the IAHCs. Flk1+ identified cells that 
reside in the basal region of the dorsal aorta, CD45+ defines the outer cells and CD41+ 
marks the cells that transit from Flk1+ to CD45+ (Yokomizo and Dzierzak 2010). 
These findings suggested that the IAHC cell composition is heterogeneous.   
Recent studies reported that IAHC formation begins from cells with polyclonal origin 
and high-proliferative activity as result of a Notch-dependent two-step process 
(Batsivari, Rybtsov et al. 2017, Ganuza, Hall et al. 2017, Zape, Lizama et al. 2017, 
Porcheri, Golan et al. 2020). Studies suggest that the IAHCs can be considered as the 
intimate supporting niche of the nascent HSCs (Porcheri, Golan et al. 2020). Emerging 
blood cells mature within the clusters to lose the endothelial properties and begin to 
express a hematopoietic genetic programme. This maturation generates intermediates 
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that are primed to became HSCs. Explant studies on IAHCs reported that endothelial 
(VE-Cadherin+) CD43-CD41+CD45- and CD43+CD41lowCD45+ subpopulations 
can differentiate into mature HSCs ex-vivo after re-aggregated and matured with 
stromal cells (Taoudi, Gonneau et al. 2008). These subsets of cells are described as 
pre-HSC type I and type II respectively and reside within the endothelial and 
subendothelial layers. The dissociation and re-aggregation approach contributed to 
identify another primed hematopoietic precursor, pro-HSC that arises at E9.5 of 
mouse embryonic development (Rybtsov, Batsivari et al. 2014). According to these 
studies, the EHT is described as a step wise process whereby mature HSCs are 
generated from HECs through a progressive maturation of defined intermediates: pro-
HSC, pre-HSC type I, pre-HSC type II (Taoudi, Gonneau et al. 2008, Rybtsov, 
Sobiesiak et al. 2011, Rybtsov, Batsivari et al. 2014).   
Advances in time-lapse vital imaging and the establishment of a novel transgenic 
mouse model allowed researchers to follow the EHT in real time (Boisset, van 
Cappellen et al. 2010). Boisset and colleagues took advantage of transgenic embryos 
(Ly6a-GFP) where the green-fluorescent protein (GFP) is under the control of the Ly-
6A (known also as Sca1) transcriptional elements (Ma, Robin et al. 2002). As Sca1 is 
a marker of HSCs, all the embryonic and adult HSCs express the GFP reporter in 
transgenic mice (de Bruijn, Ma et al. 2002).  The time lapse imaging of the EHT in 
mouse embryonic aorta showed very few HSCs bulging out from the ventral aortic 
CD31+GFP+ endothelial cells. The newly generated HSCs co-express 
CD31+cKIT+GFP+ markers and no emerging GFP+ cKit+ cells were observed before 
E10.5. The use of this mouse model contributed to the isolation of different cell 
intermediates to study the EHT and provided new insights on the transcriptional and 
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Figure 1.2 Hematopoiesis in the mouse embryo 
The first blood cells are generated at E7 of mouse embryonic development from an 
extraembryonic compartment, the YS. This first wave of generation produces primitive 
erythrocytes, macrophages and megakaryocytes. At E8.5, the second wave generates 
erythroid-myeloid progenitors (EMPs) and hematopoietic progenitors with lymphoid 
potential. Hematopoietic stem cells (HSCs) are generated during the third wave at E10.5 in 
the embryonic compartment called AGM. HSCs are also generated in the vitelline (VA), 
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1.2.3 Transcription factors involved in hematopoiesis 
The temporal and lineage-specific activation of hematopoietic programs is controlled 
by the cooperative effect of nuclear transcription factors. Transcription factors (TFs) 
are proteins that bind to DNA regulatory sequences to enable or repress the 
transcription of a group of genes. They recognise consensus DNA binding motifs that 
reside within the promoter region of downstream genes or distant genomic regions 
called enhancers. While some TFs are commonly expressed in all cell types to regulate 
the basal cellular activity, others are tissue-specific and are important in initiating the 
expression of pattern of genes that confer specific genetic programs. Scl, Lyl1, Lmo2, 
Gata2, Runx1, Meis1, Pu.1, Erg, Fli-1 and Gfi1b are conserved TFs that play pivotal 
roles in haematopoiesis (Wilson, Foster et al. 2010). Haploinsuffiencies or null 
mutations of these key hematopoietic TFs impair profoundly the function and the 
production of HSPCs, whereas genomic translocations are frequently associated with 
blood-related malignancies, particularly leukaemia and lymphomas (Shima and 
Kitabayashi 2011). 
The role of each TF in haematopoiesis has been investigated using conditional and 
temporally inducible knock out (cKO) mouse models. This was necessary since the 
full knock out of TFs such as Scl, Runx1 and Gata2 have been shown to elicit 
hematopoietic defects and midgestation embryonic lethality (Tsai, Keller et al. 1994, 
Shivdasani, Mayer et al. 1995, Yokomizo, Hasegawa et al. 2008). These in vivo 
studies examined the contribution of the TFs at different stages of embryonic 
hematopoiesis. For instance, Scl functions at early stages of hematopoiesis. Embryos 
that lack of Scl resulted in early embryonic lethality due to the absence of YS primitive 
erythropoiesis and myelopoiesis (Robb, Lyons et al. 1995, Shivdasani, Mayer et al. 
1995). Similarly, Lmo2 is critical to the YS-derived erythropoiesis and does not 
contribute for definitive haematopoiesis (Warren, Colledge et al. 1994, Yamada, 
Warren et al. 1998). On the other hand, Runx1 plays a critical role in definitive 
haematopoiesis (Cai, de Bruijn et al. 2000). Runx1-/- homozygous embryos are lethal 
at E12.5 accompanied by severe anaemia and haemorrhages (Okuda, van Deursen et 
al. 1996). The absence of Runx1 in the endothelial cells impaired the generation of 
IAHCs in the embryonic arteries and no functional HSCs were produced in the AGM 
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(North, Gu et al. 1999, Cai, de Bruijn et al. 2000, Yokomizo, Ogawa et al. 2001, Chen, 
Yokomizo et al. 2009).  
Nevertheless, it would be reductive to think that each different embryonic 
hematopoietic stage is regulated by a single TF. The acquisition of different 
hematopoietic genetic programs is the result of the combinatorial interaction between 
different TFs and co-factors. These interactions establish a variety of regulatory 
networks that define the cell identity in the hematopoietic system (Wilson, Calero-
Nieto et al. 2011). The integration of chromatin immunoprecipitation (ChIP) assay 
with bioinformatic analyses demonstrated that 7 HSPC-associated “heptad” TFs (Scl, 
Lyl1, Lmo2, Gata2, Runx1, Erg and Fli-1) interact together to regulate HSPC 
specification (Wilson, Foster et al. 2010). Functional experiments performed in 
Runx1+/-::Gata2+/- heterozygous mouse embryos confirmed the in vivo synergy 
between Runx1 and Gata2, as no double heterozygous were generated and the number 
CFU-Cs from FL of Runx1+/-::Gata2+/- embryos was reduced (Wilson, Foster et al. 
2010). 
1.2.4 Gata2 role in HSC generation 
Functional studies have reported GATA TFs (Gata 1-6) as an important class of 
regulators in embryonic development (Bresnick, Lee et al. 2010). This family of zinc-
finger TFs takes its name from the DNA consensus sequence that is able to bind 
(A/TGATAA/G). Although they share similar biochemical features, the different 
members exhibit distinct biological roles. Gata 1-3 are mainly involved in 
hematopoiesis, whereas Gata 4-6 are TFs associated with the embryonic development 
of endoderm and mesoderm derived organs such as heart and lung. Gata1 is associated 
with erythroid, eosinophils and megakaryocytes development (Tsai, Martin et al. 
1989), Gata3 with T-lymphocytes and neurons (Lim, Lakshmanan et al. 2000) while 
Gata2 is a master regulator of HSCs, multipotent hematopoietic progenitor and mast 
cell generation (Kobayashi-Osaki, Ohneda et al. 2005, Kauts, De Leo et al. 2018). 
The requirement of Gata2 for the embryonic hematopoiesis and the generation of the 
HSPCs was highlighted by in vitro and in vivo studies. Gata2 homozygous deletion 
in the germline generates no viable mice (Tsai, Keller et al. 1994). Interestingly, no 
Gata2-/- embryos survived beyond E11.5 and 67% were found dead at E10.5 
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accompanied by severe anaemia. These findings supported the hypothesis that Gata2 
is critical for the onset of the embryonic HSCs and for the establishment of definitive 
hematopoiesis. Viable mutant Gata2-/- embryos collected at E9.5 showed no defect 
in YS endothelium, vitelline vasculature and foetal membranes (Tsai, Keller et al. 
1994). Red blood cells generated from the primitive wave appeared normal although 
the total number in the YS was significantly reduced. The YS of Gata2-/- embryos 
appeared very pale and the embryos were affected from severe anaemia due to the 
impaired production of blood cells beyond primitive hematopoiesis. The generation 
of GATA-2 chimeras examined the role of Gata2 in hematopoiesis.  GATA2-/- cells 
were unable to contribute to hematopoiesis in adult hematopoietic sites such as bone 
marrow, spleen and  thymus (Tsai, Keller et al. 1994).  
Further in vivo studies have tried to describe the temporal and spatial role of Gata2 
expression in embryonic hematopoiesis. Two different Cre-LoxP transgenic mouse 
models have been used to overcome the limitations of the non-viable germline Gata2 
KO embryos. The Gata2-VEC (vascular endothelial cadherin)-Cre conditional KO 
model (Chen, Yokomizo et al. 2009) has been used to study the effect of the lack of 
Gata2 during the EHT (de Pater, Kaimakis et al. 2013) . In this mouse model, the Cre 
recombinase is under the control of the Vec promoter, whereas the LoxP sites flank 
Gata2 genomic locus. The VEC promoter is activated in endothelial cells forming the 
major embryonic vasculature. Approximately 30% of endothelial cells deleted both 
Gata2 alleles. VEC-Cre:Gata2f/f embryos are viable at E10.5-11 and survived until 
E14 despite suffering of foetal anaemia. VEC-Cre:Gata2f/f E10 and E11 whole mount 
immunostaining showed a decrease of the total number of the IAHC and the aortic 
cKit+ population. In vitro CFU-C assays of VEC-Cre:Gata2f/f AGM and FL derived 
HSPCs showed a profound reduction in the number of haematopoietic colonies. 
Similarly, transplantation of E11 HSCs isolated from VEC-Cre:Gata2f/f failed to 
repopulate lethally irradiated adult recipients. These experiments confirmed that 
Gata2 is essential for the embryonic HSC generation.   
The VAV-Cre transgenic mouse was adopted (Ogilvy, Metcalf et al. 1999, Stadtfeld 
and Graf 2005) to characterize the role of Gata2 in HSCs after their generation (de 
Pater, Kaimakis et al. 2013) . In this model, the CRE recombinase is under the control 
of the VAV pan-hematopoietic cell promoter. As consequence, up to 70% of 
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hematopoietic cells, HPCs and the newly embryonically generated HSCs lack Gata2. 
Functional analyses highlighted the importance of Gata2 for the HSC survival (de 
Pater, Kaimakis et al. 2013). Indeed, HSCs isolated from VAV-Cre:Gata2f/f AGM and 
FL did not long-term reconstitute the hematopoietic system after transplantation in 
recipient mice. In addition, the number of CFU-C colonies derived from AGM VAV-
Cre:Gata2f/f HSPCs was decreased when compared to the wild type (de Pater, 
Kaimakis et al. 2013). 
The generation of the Gata2Venus ES cell line and reporter mouse model have been 
crucial to isolate Gata2 expressing and non-expressing cells and examine their 
function and transcriptomic profile (Kaimakis, de Pater et al. 2016, Kauts, Rodriguez-
Seoane et al. 2017). In this mouse model, the Venus fluorescent reporter labels the 
Gata2 expressing cells without affecting the level and the function of Gata2 TF. 
Immunostaining performed on Gata2Venus mouse AGM at E10.5-E11 showed that 
all the IAHCs are Gata2 expressing (Kaimakis, de Pater et al. 2016). Of note, 
functional analyses performed on AGM-derived Gata2 expressing cells demonstrated 
that all the HSCs and the majority of the HPCs are Venus+ (Kaimakis, de Pater et al. 
2016). Similarly, the majority of HSPCs derived in vitro from Gata2Venus mouse ES 
cells are Venus+ (Kauts, Rodriguez-Seoane et al. 2017).  
Taken together, these experiments provided insights of Gata2 function during 
embryonic hematopoiesis. Gata2 is a pivotal haematopoietic transcription factor that 
is essential for the EHT and HSC generation, and its expression is indispensable for 
HSCs survival and expansion in the foetal liver and bone marrow after their 
production. Moreover, the generation of Gata2Venus ES cells together with 
Gata2Venus mouse models have been advantageous tools to isolate and study HSCs 
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1.3 The long road to HSC de novo generation  
The identification of hematopoietic lineage-specific TFs prompted the idea that would 
it be possible to de novo generate HSCs for therapeutic approaches. The current 
therapies to treat blood-related disorders rely on the allogenic transplantation of BM 
LT-HSCs. Sometimes, this approach is characterized by the graft-versus-host disease 
(GVHD), which is caused by the inaccurate matching of the donor human leukocyte 
antigen (HLA) with the host. The ideal alternative considers the patient autologous 
HSC transplantation. Nevertheless, this strategy has still important limitations such as 
the lack of robust protocols to enrich for HSCs and expand them ex vivo exponentially 
(Wilkinson, Ishida et al. 2019). Therefore, the derivation of human pluripotent stem 
cells (hPSCs) and the discovery of induced pluripotent stem cells (iPSCs) derived 
from somatic differentiated cells reprogrammed with pluripotency TFs (Takahashi 
and Yamanaka 2006) opened new alternative strategies to generate in vitro HSCs. 
These strategies consist of instructing hPSCs to differentiate toward HSC fate or 
reprogramming patient-derived differentiated cells with a panel of hematopoietic TFs 
to become HSCs (reviewed in (Vo and Daley 2015). Although different approaches 
have been adopted to achieve these goals, none of these methods successfully 
produced adult transplantable HSCs. Nonetheless, it is noteworthy to highlight the 
great achievements have been made to improve each of these techniques to reach a 
step closer to make HSCs.   
1.3.1 Generation of HPCs from ESC differentiation  
The possibility to generate HSCs from human pluripotent stem cells was demonstrated 
with the injection of iPSC  into immunocompromised mice (Amabile, Welner et al. 
2013).  CD34+CD45+ HSPC population was isolated from iPSC-derived teratoma 
and transplanted subcutaneously into recipient irradiated immunocompromised mice 
(Amabile, Welner et al. 2013, Suzuki, Yamazaki et al. 2013). Despite the 
demonstration that these teratoma-derived HSPCs retained only low engraftment 
potential, they were able to reconstitute the hematopoietic system after serial 
transplantations. This finding provided the first proof of concept of the possibility that 
human functional HSCs can be theoretically generated from hPSCs under defined 
conditions. Nevertheless, the direct injection of hPSCs into recipients to derive HSCs 
 
Chapter 1: Introduction 
 Antonio Maglitto - January 2021  15 
remains an uncontrolled and stochastic events that causes tumor formation into the 
hosts (Vo and Daley 2015). A deep understanding on how haematopoiesis develops 
embryonically is crucial to recreate in vitro the molecular paths to instruct hPSCs to 
produce functional LT-HSCs. Several groups made considerable and important 
progresses on generating short-lived hematopoietic progenitors from hPSCs by 
attempting to recapitulate primitive and definitive haematopoiesis in vitro. However, 
the path to generate transplantable LT-HSCs from murine and human ESCs is 
profoundly complex as they require to undergo intermediate stages before becoming 
functional HSCs. A big challenge is represented by the existence of overlapping and 
heterogeneous cell populations that are technically difficult to isolate using only cell 
surface markers.  
Different protocols have been adopted to generate in vitro HSPCs. These protocols 
exploited conditioned media supplemented with cytokines in the presence or absence 
of foetal bovine serum (FBS) (Ditadi, Sturgeon et al. 2015). The cytokines adopted in 
these media have the role to activate or inhibit pathways involved in embryonic 
haematopoiesis. The most advanced hPSC differentiation protocol enables the 
production of human primitive or definitive hematopoietic progenitors (Kennedy, 
Awong et al. 2012). In the first 72 hours of in vitro differentiation, hPSCs are primed 
into mesoderm before generating the hemangioblast intermediate (KDR+). This step 
is regulated by the balancing of the nodal-activin and Wnt-bcatenin pathways 
(Kennedy, D'Souza et al. 2007). The differential activation of these two pathways 
instructs the hemangioblast towards primitive (KDR+CD235a+) or definitive 
(KDR+CD235a-) haematopoiesis. Primitive haematopoiesis is mainly promoted by 
the activation of the nodal-activin pathway, whereas definitive haematopoiesis by the 
activation of Wnt-bcatenin (Wang and Nakayama 2009). Nevertheless, the path that 
follow the specification from the hemangioblast into hemogenic endothelium (HE) is 
widely unknown. Mouse studies demonstrated that the hemogenic endothelial cells 
(HECs) derive mainly from arterial rather than the venous vasculature (de Bruijn, 
Speck et al. 2000). These in vivo evidences raised the idea that the in vitro arterial 
specification is a pre-requisite for HECs to enter into the EHT programme (Elcheva, 
Brok-Volchanskaya et al. 2014). However, the in vivo emergence of HSCs from HECs 
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is directed by a variety of intrinsic and extrinsic signals whose role needs to be fully 
explored yet. 
1.3.2 Reprogramming PSC and differentiated cells using TFs 
Relevant improvements have been made in reprogramming iPSCs or terminally 
differentiated cells into HSC-like cells. These approaches involve the forced 
expression of few or a group of haematopoietic TFs. In this regard, the first attempt 
was made by the conditional expression of Hoxb4 in murine ES cells (Kyba, 
Perlingeiro et al. 2002). This transcription factor belongs to the big family of 
homeobox genes, a group of transcription factors that are involved in the embryonic 
morphogenesis. Hoxb4 has been described in haematopoiesis to control the expansion 
and the engraftment capacities of hematopoietic progenitors (Sauvageau, Lansdorp et 
al. 1994). The conditional expression of Hoxb4 in murine ESCs was sufficient to 
confer self-renewal capacity and long-term multilineage reconstitution after primary 
and secondary transplantations ((Helgason, Sauvageau et al. 1996, Kyba, Perlingeiro 
et al. 2002). However, recipient mice displayed a low chimerism as well as poor 
lymphoid engraftment. Of note, Hoxb4 overexpression in hPSCs enhanced the 
number of CFU-Cs but no long-term reconstitution was reported (Zhang, Beard et al. 
2008).  
Two separate groups were able to generate in vitro myeloid hematopoietic progenitors 
from hESCs using a combination of TFs. Doulatov and colleagues, used Hoxa9, Erg 
and Rora to endow myeloid progenitors with in vitro self-renewal and multilineage 
potentials whereas other two transcription factors (Sox4 and Myb) were sufficient to 
confer short-term engraftment. Conversely, Elcheva and colleagues were able to direct 
the production of pan-myeloid and erythro-megakaryocytic lineages with different 
groups of TFs: Gata2, Etv2 and Tal1, Gata2 respectively. However, in none of these 
studies were the reprogrammed myeloid progenitors able to long-term engraft 
recipient immunocompromised mice (Doulatov, Vo et al. 2013, Elcheva, Brok-
Volchanskaya et al. 2014). 
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1.3.3 Direct reprogramming of differentiated cells 
Some scientists embraced the possibility to directly reprogram somatic cells into HSC-
like phenotype. The concept of direct reprograming describes the approach of 
switching the fate of differentiated cells directly into HSPCs without transit through a 
pluripotent stage. This possibility encouraged some groups to seek the minimal and 
sufficient combination of TFs that are able to convert mouse fibroblasts into an HSC-
like cells. Taking advantage of an engineered mouse (H2B-GFP) reporter fibroblast 
cell line, Pereira and colleagues, identified a minimal combination of 4 TFs (Gata2, 
Gfi1b, cFos and Etv6) that able to activate the HE program in differentiated mouse 
embryonic fibroblasts (MEFs) (Pereira, Chang et al. 2013). Reprogrammed HECs 
differentiated into HSC-like phenotype after coculturing with stromal cells. Although 
no in vivo functional experiments were performed to confirm the generation of LT-
HSCs, these cells reprogrammed HSC-like cells generated CFU-C colonies after been 
reaggregated with mouse placental cells (Pereira, Chang et al. 2013). A similar 
approach was adopted by Batta and colleagues. With the ectopic expression of 5TFs 
(Erg, Gata2, Lmo2, Runx1c, Scl), the authors converted embryonic and adult murine 
fibroblasts into HPCs with short term engraftment potential. Of note, the 
reprogramming efficiency was improved using p53-/- fibroblasts (Batta, Florkowska 
et al. 2014). The two aforementioned studies gave an important contribution into our 
understanding of which factors may contribute to reprogramming of somatic 
differentiated cells into hematopoietic fate and what limitations still remain.  
 Developmentally appropriate niches are an essential source of supportive 
microenvironment for HSC generation and thus, are an important consideration in 
attempting de novo production of HSCs. The limitation of MEFs as a supportive niche 
is in their lack of plasticity and parallel niche development. The niche plays a role in 
not only affecting hematopoietic development and differentiation through activating 
TF expression but also affects the HSC epigenetic landscape. The following studies 
benefited from these considerations and have achieved the best results so far reported 
in HSC reprogramming. Rather than differentiated cells, Riddell and colleagues 
reprogrammed haematopoietic lymphoid progenitors (Pro-B cells) with a pool of 
6TFs that have been selected in vivo (Hlf, Runx1t1, Pbx1, Lmo2, Zfp37, Prdm5). Pro-
B cells were transfected with doxy-inducible lentiviral particles carrying these 6TFs 
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and injected into recipient mice. The activation of the 6TF together with the supportive 
in vivo microenvironment contributed to the generation of induced (i)HSCs. Although 
the transcriptome profile of the iHSCs appeared to be fairly comparable with the 
native HSCs, in vivo functional analyses on iHSCs resulted poorly reproducible 
(Riddell, Gazit et al. 2014). Lis and colleagues took advantage of the ontological 
similarities between the ECs and HSCs to transduce adult murine ECs with the FGRS 
TFs (FosB, Gfi1, Runx1 and Spi1) and propagate them on a vascular niche 
microenvironment (Lis, Karrasch et al. 2017). The angiocrine factors provided by the 
microenvironment were crucial for the conversion of ECs into stable and self-
renewing HSCs (called rEC-HSCs). These rEC-HSCs retained long term engraftment 
potential and hematopoietic reconstitution of both myeloid and lymphoid lineages. 
The same FGRS TFs were able to reprogram human umbilical vein-ECs (HUVEC) 
into hMPPs. These reprogrammed induced MMPs had in vivo engraftment capacity 
in recipient immunodeficient mice but lacked donor-derived lymphoid lineage 
contribution (Sandler, Lis et al. 2014). The most recent study combined the 
morphogen-directed differentiation of hPSCs to generate the HE. Afterwards, the in 
vitro derived HECs were successfully converted in iHSCs with 7 in vivo selected TFs 
(Erg, HoxA5, HoxA9, HoxA10, Lcor, Runx1 and Spi1). However, the conversion is 
not consistently reproducible and the iHSCs lack of robust engraftment. Moreover, 
the molecular and functional properties need to be carefully evaluated (Sugimura, Jha 
et al. 2017). 
All together, these studies demonstrated that HSC-like cells are produced by a 
combination of intrinsic and extrinsic factors, i.e. the expression of key TFs and 
signals sent by the surrounding microenvironment. The generation of LT-HSCs in 
vitro can be obtained only with a deep understanding of the embryonic genetic profiles 
and the signalling pathways that drive the HECs to become HSCs. Nonetheless, these 
complex regulatory networks remain largely unknown. 
1.4 Gpr56 is a novel regulator of HSC generation 
In a study carried out by our lab, Solaimani et colleagues analysed the differentially 
expressed genes (DEGs) between highly enriched ECs, HECs and HSCs to identify 
novel molecules that regulate the emergence of HSCs in vivo (Solaimani Kartalaei, 
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Yamada-Inagawa et al. 2015). Using the Ly6A-GFP reporter mouse model with CD31 
and cKit markers, the authors profiled the transcriptomic signature of aortic ECs, 
HECs and HSC during EHT. The comparative analysis of the transcriptome of each 
population allowed to find 139 DEGs in ECs versus HECs and 340 DEGs in HECs 
versus HSCs. We found that most of the hematopoietic genes become active within 
the HEC population, whereas the endothelial signature is gradually lost as ECs 
progress towards HECs. Of note, a discrete number of angiogenetic genes were 
expressed in the HECs as compared to the ECs, demonstrating the crosstalk between 
the HECs and the supportive vascular niche. The study revealed Gpr56 as novel 
potential regulator of HSC emergence. Gpr56 is the highest differentially expressed 
gene in the transition from HECs into HSCs. Interestingly, chromatic immuno-
precipitation analysis reported Gpr56 being a target of the heptad transcription factors 
as they bind the Gpr56 -37 upstream predicted enhancer region. Functional analyses 
performed in zebrafish demonstrated that Gpr56 is required for the EHT. gpr56 
knockdown in zebrafish severely reduced the frequency of HSCs (cmyb+) and 
hematopoietic progenitors (CD41+). Conversely, the injection of Gpr56 transcripts 
(murine and zebrafish) in morpholino larvae, rescued the production of HSPC 
population and revealed ectopic hematopoiesis (Solaimani Kartalaei, Yamada-
Inagawa et al. 2015). These results highlighted the crucial role of Gpr56 during the 
EHT.  
The next section will provide insights on the structural and molecular features of this 
important receptor with a specific focus on its role in tissue development and 
malignancies. 
1.4.1 Gpr56 structure and molecular features  
Gpr56 (ADGRG1) is a well conserved orphan receptor that belongs to the largest G-
protein coupled receptor (GPCR) superfamily. GPCRs encoded by the human genome 
are grouped into five families: glutamate, rhodopsin, adhesion, frizzled and secretin. 
Gpr56 is part of the adhesion GPCR (aGPCR) family which represents the second 
largest with 33 members (Fredriksson, Lagerstrom et al. 2003, Schioth and 
Fredriksson 2005). 
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The aGPCR family can be further divided into nine subfamilies: ADGRL 
(lathrophilins), ADGRA, ADGRC (CELSRs), ADGRD, ADGRG, ADGRV, 
ADGRE, ADGRF and ADGRB, most of which share a share a common protein 
architecture. The molecular structure presents a twofold protein structure that consist 
of a long extracellular domain (ECD) of ~320-5878 residues, a highly conserved 7-
pass transmembrane (7TM) domain followed by an intracellular domain (ICD) which 
is responsible for initiating the signalling cascade upon activation. aGPCR family 
possesses a unique auto-proteolytical cleavage at the GPCR proteolysis site (GPS) 
within a conserved GPCR autoproteolysis inducing domain (GAIN) (Lin, Chang et al. 
2004). The GAIN domain is the only shared domain among almost all aGPCRs (32 
out 33, is absent ADGRA1) and it consists of domain A (6 alpha-helices) and domain 
B (twisted beta-sandwich with 13 beta-strands and 2 alpha-helices (Arac, Boucard et 
al. 2012). As part of aGPCR family, Gpr56 is characterized by a 7TM, a 
juxtamembrane GAIN domain and a ECD that mediates the adhesion-related 
interactions with extracellular signals (Langenhan, Aust et al. 2013). Although the 
biological role of the ECD remains poorly understood, the 7TM is responsible to 
initiate the signalling cascade whereas the GAIN domain undergoes to post-
translational modifications along protein maturation. Indeed, the receptor maturation 
culminates with an autoproteolytic cleavage within the GAIN domain which generates 
two different fragments non-covalently associated on the plasma membrane: N-
terminal fragment (NTF) and C-terminal fragment (CTF) that contains a cryptic 
tethered peptide called Stachel domain (Figure 1.3). The Stachel domain has been 
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Figure 1.3 Gpr56 protein structure and mechanism of activation  
Gpr56 belongs to the adhesion GPCR family. It consists of an extracellular domain (ECD), 
which contains the GAIN domain and the N-terminal fragment (NTF), a conserved 7 
transmembrane domain (7TM) and an intracellular region. The exposure of the Stachel 
domain due to mechanical forces or upon the binding of the NTF to an extracellular ligand, 
triggers the downstream signalling cascade.  
 
These studies prompted the proposal of two activation mechanisms: cleavage 
independent (Kishore, Purcell et al. 2016) and cleavage dependent (Stoveken, 
Hajduczok et al. 2015) (Figure 1.3). Two non-mutually exclusive cleavage-dependent 
models have been suggested for Gpr56 activation. According to the first model 
(“shedding”), the Stachel domain is exposed by the ligand-dependent dissociation of 
the NTF from the CTF domain (Liebscher, Schon et al. 2014, Stoveken, Hajduczok et 
al. 2015), whereas the alternative model suggests that the presence of the NTF portion 
per se inhibits the receptor activity. As a consequence, the deletion of the NTF 
constitutively activates the downstream signalling through the 7TM domain (Paavola, 
Stephenson et al. 2011). From the cytosolic portion of the 7TM domain the internal 
signalling cascade starts with the phosphorylation of the heterotrimeric Gα12/13 and 
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Rho GTPase protein family: RhoA. RhoA becomes active by exchanging guanosine 
diphosphate (GDP) to guanosine triphosphate (GTP) thanks to the guanidine 
nucleotide exchange factor (GEF). The resulting activated RhoA-GTP regulates 
important biological processes such as actin cytoskeleton reorganization, myosin 
contractility, cell migration and proliferation (Ihara, Muraguchi et al. 1998, Jaffe and 
Hall 2005, Hall 2012).  
Such a variety of biological responses and the wide expression of Gpr56 in different 
cell types presented the idea that different ligands might activate the receptor. To date, 
the molecules known to activate Gpr56 are two natural ligands, collagen III (Col3a) 
and transglutaminase2 (TG2), one small agonist molecule, 3--acetoxydihyl-
drodeoxygedunin (3--DOG) and a 19-amino-acid synthetic peptide that mimics the 
Stachel domain (P19) (Zhu, Luo et al. 2019). These ligands activate Gpr56 in different 
ways. Zhu et colleagues performed experiments examining the ligand-dependent 
mechanism of Gpr56 activation (Zhu, Luo et al. 2019). By taking advantage of a 
cleavage-deficient receptor (GPR56H381S), they demonstrated that both collagen III 
and TG2 ligands activate the receptor via a Stachel-dependent mechanism. According 
to this model, the binding of these ligands to the extracellular portion of the receptor 
causes conformational changes which lead to the NTF shedding. The exposure of the 
Stachel domain triggers the 7TM activation. Differently from collagen III, TG2-
mediated activation requires the simultaneous binding of the ligand with the NTF 
receptor domain and a constituent protein of the extracellular matrix: laminin. On the 
other hand, the non-natural agonist molecules (3--DOG and P19) engage the 
receptor orthosteric site to interact with the Stachel domain directly. P19 acts as 
natural tethered agonist as it is capable to reach the orthosteric domain regardless 
receptor cleavage, whereas 3--DOG is unable to activate the Gpr56 uncleavable 
form. This might be explained by considering the Gpr56 spatial conformation. The 
NTF three-dimensional conformation of the uncleavable receptor might hamper the 
interaction between 3--DOG and the Stachel domain to prevent the signalling 
cascade (Zhu, Luo et al. 2019).  
Altogether, these insights enforce the crucial role of the Stachel domain. The exposure 
or the directly binding of the Stachel domain is sufficient to modulate the receptor 
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activity. Several groups have used this feature to develop large-scale in vitro cell-
based assays to study a wide range of aGPCRs with similar molecular structure. These 
assays rely on the dynamic expression of downstream effectors such as TCF, SRE, 
SRF, NFAT. The expression levels of the transcriptional regulators correlate with the 
receptor activity (Shashidhar, Lorente et al. 2005, Kishore, Purcell et al. 2016). In 
vitro drug discovery platforms might take advantage of these well-established assays 
to identify new cell specific agonist and antagonist compounds. 
1.4.2 Biological functions of Gpr56 
Despite Gpr56 is largely involved in physiological processes, the pathological 
conditions such as cancer, cardiovascular and neuronal diseases contributed 
profoundly to understand its protein structure and signalling pathway. As membrane 
receptor, Gpr56 is a suitable pharmacological target for therapeutic approaches and 
drug discovery screenings. 
The Gpr56 receptor has been widely studied in cerebral cortical development 
(Langenhan, Piao et al. 2016) . It is expressed on neural progenitor cells (NPCs) that 
undergo a “radial migration” which leads to the formation of the mature neurons. 
Patients with mutations in GPR56 suffer from epilepsy, mental retardation and 
language impairment: a neurological disorder known as bilateral frontoparietal 
polymicroglia (BFPP) (Ke, Ma et al. 2008) . These mutations cause a poor expression 
of the receptor at the cell membrane as Gpr56 is retained in the ER/Golgi (Santos-
Silva, Passas et al. 2015). Other studies examined the role of Gpr56 in zebrafish and 
murine oligodendrocyte development (Ackerman, Garcia et al. 2015, Giera, Deng et 
al. 2015). In these studies, the authors demonstrated that Gpr56 is abundantly 
expressed during the early stages of oligodendrocyte development and gradually 
decrease in mature myelinating oligodendrocytes. In the absence of Gpr56, 
oligodendrocytes were specified normally but hypomyelinated and reduced in number 
due to a decrease in the oligodendrocyte progenitor cell (OPC) proliferation. In 
addition, Gpr56 regulates OPC proliferation via Gα12/13 and RhoA signalling 
pathway (Luo, Jeong et al. 2011, Ackerman, Garcia et al. 2015, Giera, Deng et al. 
2015). Gpr56 is also involved skeletal muscle cell development as it is upregulated 
during the early fusion of human myoblasts (Cerletti, Molloy et al. 2006). Its 
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expression is found in myocytes, in the nascent myotubes and it supports myoblast 
differentiation via the activation of SRE and NFAT signalling. Although Gpr56-
deficient myoblasts decreased their fusion capacity in vitro, no relevant defects have 
been reported in the phenotype of muscles of Gpr56 knock-out mice (Wu, Doyle et 
al. 2013, White, Wrann et al. 2014).  
The expression of Gpr56 was found in different type of cancer. Xu and colleagues 
performed a gene expression analysis on metastatic variants of melanoma cells. They 
found that Gpr56 is remarkably downregulated on highly metastatic variants, whereas 
the TG2-mediated GPR56 activation contributes to suppress melanoma metastasis and 
tumor growth (Xu, Begum et al. 2006). Other studies supported the evidence that the 
dysregulated expression of Gpr56 is implicated in several cancers such us pancreatic, 
colon, ovarian, hematopoietic and glioblastoma/astrocytoma (Shashidhar, Lorente et 
al. 2005, Ke, Sundaram et al. 2007, Liu, Huang et al. 2017). Amongst them, it is 
important to highlight the relevance of GPR56 in leukemia. 
1.4.3 The relevance of Gpr56 in leukaemia  
Compelling studies demonstrated that the prolonged and high level expression of 
Gpr56 in blood cells correlates with hematological malignancies and, specifically, 
with acute myeloid leukaemia (AML) (Daga, Rosenberger et al. 2019). Patients 
affected by AML suffer an abnormal proliferation and differentiation of a myeloid 
stem cells (blasts). The onset of such uncontrolled cell proliferation (leukemogenesis) 
is mainly driven by a combination of two different events: chromosomal 
translocations and genomic mutations. Such mutations alter the physiologic function 
of epigenetic regulators or effector proteins involved in proliferative pathways (De 
Kouchkovsky and Abdul-Hay 2016). Although the chemotherapy allows the complete 
remission for the 60% of the AML patients, the remaining relapse. The high rate of 
relapsing is mainly attributed to few leukemic stem cells (LSCs) that persist after the 
standard therapy. These aggressive LSCs are heterogenous and share the majority of 
the biological features with healthy HSCs: self-renewal, quiescence and the ability to 
resist to drug treatments (Kreso and Dick 2014, Fong, Gilan et al. 2015). Therefore, it 
is necessary to identify therapeutic targets to eradicate those aggressive LSCs and find 
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prognostic factors to discriminate responsive patients from those that relapse after 
standard therapies.  
Ng and colleagues contributed to develop a rapid and powerful prognostic tool to 
screen high-risk AML patients before starting chemotherapy (Ng, Mitchell et al. 2016) 
. In this study, gene expression analysis was performed on LSCs isolated from 78 
AML patients. From this analysis, the authors generated a 17-gene score (LSC17) 
panel that defines biomarkers related to the “stemness” properties of LSCs. 
Interestingly, they found GPR56 as part of these highly selected biomarkers that 
characterize the LSCs signature (Ng, Mitchell et al. 2016). Different studies 
performed in patient derived AML samples, found that Gpr56 expression identifies 
aggressive subset of LSCs (Pabst, Bergeron et al. 2016). To identify novel 
determinants in primary human AML, LSCs from a cohort of 179 patients were 
analysed combining RNA-seq with functional in vivo assays. Gpr56 was found to be 
a marker of leukemic subpopulations with high engrafting capacity in NOD-Scid-
gamma immunodeficient mice. LSC activity fall within Gpr56+CD34+ and 
Gpr56+CD34- subpopulations but not in the Gpr56- fraction. Furthermore, high 
GPR56 expression was found in the enriched LSC in CD34+CD38- sub compartment 
when compared to CD34+CD38+ or CD34-. Of note, the high level of Gpr56 protein 
correlates with an upregulation of drug efflux transporters ABCG1, ABCC1 and 
ABCA2 indicating a possible association of Gpr56 expression and drug resistance 
(Pabst, Bergeron et al. 2016, Daga, Rosenberger et al. 2019).  
The association of high GPR56 expression and drug resistance LSCs emerged also in 
another study. In this work, Saito and colleagues found that GPR56 is highly 
expressed in EVI1highAML, a class of chemotherapy-resistant AML with poor 
prognosis (Barjesteh van Waalwijk van Doorn-Khosrovani, Erpelinck et al. 2003, 
Saito, Kaneda et al. 2013). The high expression of GPR56 in EVI1highAML cells led 
to an improved cell adhesion and apoptotic resistance whereas its downregulation 
reduced their cellular adhesion, viability and increased their susceptibility to 
chemotherapeutic agents (Saito, Kaneda et al. 2013). These evidences prompted the 
idea to consider Gpr56 as potential therapeutic target to eradicate those chemo 
resistant LSCs present in EVI1high and in most of the AML subcategories. 
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1.4.4 Other GPCRs involved in hematopoiesis 
To date, only a few GPCRs are known to play a role in hematopoiesis in vivo and in 
vitro. Apelin receptor (APLNR) is a GPCR expressed on ECs in the mouse embryonic 
AGM region and in vitro hPSC-derived ECs that differentiate into the hematopoietic 
lineage. Although its role in vivo has not been determined, APLNR activation enhances 
blood cell formation in vitro (Yu, Hirst et al. 2012). A pulse of Apelin ligand added 
in the early stage of hESC differentiation enhanced the EB size, the number of 
hemangioblast colony-forming cells (BI-CFCs) and induced the growth of ESC-
derived endothelial cells (Yu, Hirst et al. 2012). Another recent study performed in 
mouse ESCs demonstrates that Apelin receptor defines a transient population of ESC-
derived mesodermal cells committed to hematopoietic fate. In vitro hematopoiesis is 
impaired in Apelin-null mouse ESC, leading a significant reduction of HPCs (Jackson, 
Fidanza et al. 2020). Interestingly, the activation of Apelin pathway in AGM explants 
decreases the number of LT-HSCs and promotes myeloid differentiation (Jackson, 
Fidanza et al. 2020). Other GPRCs are known to regulate HSC generation through the 
modulation of the EHT. Thrombin Receptor (F2r) is a GPCR belonging to the 
proteinase-activated receptors (PAR) family and it is activated by its ligand thrombin 
(F2). Although F2r expression is required for vascular development, Yue and 
colleagues demonstrated that it might act as molecular switch to keep the balance 
between vascular and haematopoietic fate decisions. Using mESC and zebrafish 
model systems, they showed that F2r negatively regulates EHT and HSC generation 
via RhoA/ROCK pathway. Indeed, the inhibition of the F2r-RhoA/ROCK pathway 
promotes the EHT transition towards the generation of haematopoietic cells whereas 
its overexpression showed the opposite effect (Yue, Li et al. 2012).  
Another GPCR involved in the EHT is Gpr183. In zebrafish, this receptor is the most 
upregulated GPCR expressed in those ECs that undergo EHT (Zhang, He et al. 2015). 
Functional analyses demonstrated that, upon activation, Gpr183 modulates HSPC 
generation through the repression of the Notch signalling pathway. Conversely, 
Gpr183 inhibition resulted in a persistent activation of Notch1 that culminates with 
the abrogation of EHT and the HSPC generation (Zhang, He et al. 2015). Another 
study investigated the relationship between GPCRs and transcription factors (TFs). 
Gao and colleagues used bioinformatic analyses to identify GATA-2 induced GPCRs 
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that promote HSPC generation. They found that the expression of Gpr65 suppresses 
haematopoiesis by repressing a genomic +9.5 Gata2-cis element that enhances Gata2 
expression and EHT in vivo (Gao, Wu et al. 2016).  
Taken together GPCRs are involved in EHT and HSC generation, normal function 
and malignancy. Most importantly to our study is the Gpr56 receptor. Its expression 
and function are poorly characterized and hence, how Gpr56 acts in the production of 
HSC in vivo, in vitro and in leukemic stem cells is the focus of my thesis.   
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1.5 Hypothesis 
Gpr56 is required for HSPC function and production in mammals.  
1.6 Aims 
To investigate the functional role of murine and human HSPCs when Gpr56 
expression is altered.  
 
1.  To test the function of HSPCs that lack Gpr56 
a. In vivo, using VEC:Cre and VAV:Cre Gpr56 cKO mouse models 
(Chapter 3) 
b. In vitro, using Gpr56 knock out (KO) ESC line (Chapter 4)   
 
2. To investigate the functional output of human iPSC-derived HSPCs that 
overexpress GPR56 during hematopoietic differentiation (Chapter 5) 
a. Establishment of an inducible iPSC line that overexpresses GPR56 at 
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2  MATERIALS AND METHODS  
2.1 Mice and embryo production 
Gpr56fl (Giera, Deng et al. 2015), VavCre (Stadtfeld and Graf 2005) and VECCre 
(Chen, Yokomizo et al. 2009) mouse colonies were established. Embryos were 
generated by crossing Gpr56fl (C57BL/6) mice with VavCre:loxGpr56 or 
VECCre:loxGpr56 (C57BL/6HsdJOla) animals (all 2-6 months old). The day of 
vaginal plug discovery was E0 and embryo staging was by somite pair counts. Ly5.1 
mice (B6.SJL-PtprcaPepcb/BoyCrl, 2-4 months old) were recipients for 
transplantations. All mice were housed and bred in University of Edinburgh animal 
facilities in compliance with Home Office regulations and all procedures performed 
under a Home Office UK Project License. 
2.2 Flow cytometry 
Embryo cells. Yolk sacs (YS) were digested (37°C, 45’) in 0.125% type 1 collagenase 
(C0130, Sigma-Aldrich) and washed and resuspended in PBS+10%FBS. FL cells 
were obtained by passing the tissue (5x) through a 30G needle. YS cells were stained 
with CD41- eFluor450, CD31-BV605, CD16/32-PE, c-Kit-APC and CD45-AF450 
(Table 3.1) and FL LSK-SLAM (CD3-B220-Gr1-Ter119-NK1.1-CD48- and 
Sca1+cKit+CD150+) were sorted. PBS/FBS washed cells were run on a LSR Fortessa 
(BD Bioscience) and data analysed with FlowJo v10 (BD) software. Dr. Samanta 
Antonella Mariani and Chris Vink helped with the embryo dissections. Dr. Samanta 
Antonella Mariani performed the in vivo FACS analyses. QMRI Flow Facility helped 
in setting up the flow cytometric gates and sorted the cells of interest.  
ES cells. Day 6 and 10 differentiated mouse EBs were PBS-washed and dissociated 
(37°C, 5-10 minutes) in 500l TrypLE Express (Gibco). Cells were incubated (4°C, 
30 minutes) with antibodies against CD41, CD45, CD16/32, and cKit (Table 3.1). 
Washed cells (10% FBS/PBS) were run on Aria III/Fusion (BD) and results analysed 
with FlowJo software. Dead cell exclusion was by Hoechst 33342 (Invitrogen) and 
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gates set based on unstained WT and fluorescent-minus-one (FMO) controls. Sorted 
cells were collected in 50% FBS/PBS buffer for functional analyses (CFU-C assay). 
2.3 Hematopoietic assays 
CFU-C. LSK-SLAM sorted FL cells (CD3-B220-Gr1-Ter119-NK1.1-CD48- and 
Sca1+cKit+CD150+) were cultured (100 LSK-SLAM per plate) in Methylcellulose 
(M3434, Stem Cell Technologies, CN; 37C, 5%CO2) and colonies counted after 10 
days.  
LTR-HSC. FL LSK-SLAM cells were injected intravenously into irradiated Ly5.1 
recipients (2x4.5 Gy γ-irradiation) at 1 FL/recipient or 3, 10 or 30 LSK-SLAM 
cells/recipient. For secondary transplantations, LSK bone marrow cells of primary 
recipients were injected into Ly5.1 irradiated mice. After 4, 16 and 23 weeks, 
peripheral blood was analysed by CD45.1- and CD45.2- flow cytometry. Multilineage 
analysis on bone marrow, spleen, thymus and lymph nodes was performed 23 weeks 
post-transplantation. Recipient mice were considered reconstituted at ≥2.5% donor-
derived cells. Chris Vink performed the transplantations.  
2.4 Molecular analyses  
Genotyping. DNA from CFU-C colonies, ear notches or sorted cells was extracted in 
PCR Buffer with Non-Ionic Detergent (PBND: 50mM KCl, 10mM TrisHCl, pH 8.3, 
2.5mM MgCl2, 0.1mg/ml gelatin, 0.45% (v/v) Igepal/NP40, 0.45% (v/v) Tween20) + 
Proteinase K (10mg/ml, 1h, 55°C) and heat-inactivated (95°C, 10’). 1µl of solution 
was used for Gpr56 PCR. Touchdown PCR program was used to genotype embryos 
using Kapa HiFi Hotstart DNATaq Polymerase, according to the manufacturer 
protocol. PCR amplification protocol:  
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Gene Ruler 1kb Plus (Thermo Scientific cat# 11511635) was used as DNA ladder in 
the agarose gel. Dr. Carmen Rodriguez Seoane performed the embryo genotypes. 
RT-qPCR analysis. RNA was isolated using the RNeasy Micro kit (Qiagen). cDNA 
was synthesized with oligo(dT) (Invitrogen) and SuperScriptIII (Life Technologies). 
qRT PCR was performed with FastSybrGreen master mix (Life Technologies). See 
Table 3.2 for primers. 
Cloning. The mCherry-p2a-hGPR56, mCherry-p2a-SP-his-hGPR56 and mCherry-
p2a-SP-hGPRCA cassettes were generated using Gibson Assembly mix (NEB, cat 
#E5510S) and cloned into the pcDNA3.1+ expression plasmid (Addgene #V790-20). 
The Gibson assembly ligates two or more adjacent fragments seamlessly in a one-step 
isothermal reaction (50˚C). This is possible by generating fragments that overlaps ~15 
to 40 base pairs at their 5’ and 3’ ends. These fragments are mixed together with the 
Gibson Mastermix, which contains an exonuclease, DNA polymerase and a DNA 
ligase.  The exonuclease chews the 5’ ends of each fragment, so the fragments anneal 
as they share overlapping sequences. The DNA polymerase fills the gaps and the DNA 
ligase seals the nicks (Gibson, Young et al. 2009). 10-beta NEB (New England 
Biolabs #C3019H) competent bacteria were transformed according to the 
manufacturer protocol. Bacteria were PCR-screened using a set of primes that span 
from mCherry to hGpr56 genes (Table 3.2). The PCR was performed following the 
Taq Polymerase (cat#10342053) manufacturer protocol. GPR56 full length coding 
sequence (2082bp) was PCR amplified from BC-GPR56 plasmid (BC-GPR56 was a 
gift from Lei Xu, Addgene plasmid #44197). The donor AAVS1-TetOn backbone was 
kindly provided by Forrester Lab. All the regulatory elements of the Tet-ON system 
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are included within the AAVS1 HAs. The backbone contains the neomycin resistance 
gene to select those cell clones that positively integrate the donor vector. In addition, 
the backbone holds a single SalI restriction enzyme (RE) sites to insert the hGPR56 
cassettes (Figure 5.4 A). The mCherry and hGRP56 full length sequences were 
amplified from Addgene plasmids #58476 and #52297 respectively. The amplicons 
designed for Gibson Assembly were PCR-amplified using the Phusion High-Fidelity 
Taq Polymerase (cat#M0530S) following the manufacturer protocol. Primers used for 
Gibson Assembly are listed in Table 3.2. AAVS1-TetOn backbone was kindly 
provided by Forrester laboratory. NEB10-beta competent E.coli were transformed 
with the ligated plasmids according to the manufacturer protocol. Plasmid digestions 
were performed using New England Biolabs restriction enzymes. Gene Ruler 1kb Plus 
(Thermo Scientific cat# 11511635) was used as DNA ladder on agarose gel in all the 
PCR and enzymatic products. 
Western blotting. 106 ESC were washed 2x with PBS, re-suspended in ice cold RIPA 
buffer + protease and phosphatase inhibitors (ThermoFisher) and incubated (30’, ice). 
Samples were sonicated and centrifuged (maximum speed, 15’). Total protein in 
supernatant was quantified using BSA kit (BioRad). Equal amounts of protein for each 
sample were boiled (95°C, 5’) in SDS sample buffer (BioRad), were separated in 
SDS- polyacrylamide gel (NuSTep) and transferred (30’; 20V) to a nitrocellulose 
membrane (Amersham). The membrane was blocked (5% semi-skimmed milk in 
TBS-Tween20) and blotted overnight (4°C, 1.5% semi-skimmed milk in TBS-Tween) 
for Gpr56 detection. Incubation for −Actin detection was at RT (2hr). Membranes 
were washed (3x, 5’) in TBS-Tween and blotted with HRP-conjugated secondary 
antibodies (RT, 1hr). HRP signal was detected by Odyssey FC (Li-Cor) using Image 
Studio Lite (Li- Cor) software. See Table 3.1 for antibodies. Dr. Samanta Antonella 
Mariani helped in performing western blot assay. 
CRISPR/Cas9 genome editing. G2V.56-/-, G2V.56-/-/97-/- were generated following the 
protocol published by (Ran, Hsu et al. 2013). In brief, gRNAs were designed using e-
CRISP tool (http://www.e-crisp.org/E-CRISP/index.html) and top score gRNAs 
(Table 3.2) were selected and cloned into pSpCas9(BB)-2A-GFP (Addgene plasmid 
ID: 48138) using BbsI restriction enzyme (R00539, New England Biolab). The 
resulting CRISPR/Cas9 plasmids were transfected into G2V ESC (provided by Dr. 
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Mari-Liis Lukke) using DreamFect (OzBiosciences, Cat#DF40500) according to the 
manufacturer protocol. Transfected GFP positive cells were single-cell sorted into 96 
multiwell plates in a feeder layer of mouse embryonic fibroblasts (MEFs) and 
expanded for 5 to 7 days. Single-cell derived colonies were transferred into bigger 
MEF-covered plates (48 and 24-multiwell plates) for further expansion. RNA was 
extracted (RNeasy Micro kit, Qiagen cat# 74004) to assess the mRNA level of Gpr56 
and Gpr97 (primers, Table 3.2). DNA was extracted and used for the Surveyor Assay 
(IDT, cat#706020) following the manufacturer protocol. The Surveyor Assay was 
used to detect mutations and polymorphisms in a specific genomic sequence. Genomic 
heteroduplexes made of wild type and gRNA-targeted sequences are recognised and 
cleaved by the surveyor nuclease at the site of any single nucleotide polymorphism or 
indels mutations.  
2.5 Mouse ES cell maintenance and differentiation 
IB10 ESCs (WT, G2V, G2V.56-/-, G2V.56-/-/97-/-, genetic background C57BL/6 129/Ola were 
cultured (37°C, 5% CO2) on irradiated mouse embryonic fibroblasts (MEFs) in ES 
medium, daily refreshed (DMEM, Lonza), 15% FCS (HyClone), 2mM GlutaMAX, 
1mM Na-pyruvate, 1%P/S, 50mM ß-mercaptoethanol (all Gibco), 0.1mM non-
essential amino acids (Lonza), 1,000U/mL LIF (Sigma). Karyotype on IB10 ESCs 
was performed routinely by Dr. Carmen Rodriguez Seoane. IB10 karyotype did not 
show any chromosomic alteration. However, karyotypes on the newly generated 
G2V.56ko and G2V.56ko97ko ESC lines need to be performed to exclude genomic 
anomalies.   MEFs (200.000cells per well of 24multiwell-plate) keep ESCs 
undifferentiated, in defined single cell-derived colonies. 1 day prior splitting ESCs, 
MEFs were plated in gelatine (0.01%) coated plates. When ESCs reach ~50% 
confluency, 500ul/well of Trypsin/EDTA was added into single well and cells were 
incubated at 37C for 5 minutes. Cells were spin down (1000rpm, 5 minutes, room 
temperature) and resuspended in complete medium. Over time, the splitting procedure 
allows to remove differentiating cells. To induce EB formation, confluent ESCs were 
trypsinized and MEFs depleted by 30’ incubation in EB medium (Iscove’s modified 
Dulbecco’s medium (IMDM), 15%FCS (HyClone), 1%P/S (Gibco)). EB formation 
was induced (40 rpm; 25x103 cells/mL) in EB medium, 2mM GlutaMAX (Gibco), 
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50mg/mL ascorbic acid (Sigma), 4x10-4M monothioglycerol (Sigma), 300mg/mL 
transferrin (Roche) and supplemented with 5% proteome-free hybridoma medium 
(Gibco) on day 3. From day 6 onward, 100ng/mL stem cell factor, 1ng/mL interleukin-
3, 5ng/mL interleukin-11 (all from Peprotech) were added. 2,000 to 10,000 V+ and 
V- cells were FACS sorted to perform gene expression analyses.  Dr. Carmen 
Rodriguez Seoane helped in maintaining and differentiating mESCs. 
2.6 Human SFCi55 maintenance and differentiation  
To study the functional role of hGPR56 in human hematopoiesis, I generated an 
inducible iPSC line (SFCi55) that will express constitutively active GPR56 by adding 
doxycycline in the culture media. The workflow is shown in Figure 5.9 SFCi55 are 
targeted with the AAVS1-Tet-On-mCherry-p2a-hGPR56CA donor vector, which 
constitutively activates the GPR56 downstream signalling cascade upon expression 
(Paavola, Stephenson et al. 2011) (Figure 5.9 A). SFCi55 that integrated the donor 
vector will be selected by neomycin (Figure 5.9 B) and PCR screened to confirm the 
correct genomic location of the AAVS1-Tet-On-mCherry-p2a-hGPR56CA (Figure 5.9 
C). The selected clones will be validated to test the mCherry and hGPR56 expression 
induced by the doxycycline (Figure 5.9 D).  
The SFCi55 iPSC line was kindly provided by Forrester laboratory (Yang, Ma et al. 
2017). Cells were maintained and expanded into 6 multiwell plates coated with 
CELLstart xeno-free substrate (Thermofisher Scientific cat#A1014201) in serum-free 
medium (StemPro hESC SFM, Thermofisher Scientific, cat#A1000701), ß-
mercaptoethanol (0.1mM, Gibco), BSA 25% and bFGF (20ng/ml). SFCi55 cells grow 
as well-defined round-shaped colonies. Medium was daily refreshed, and cells were 
constantly monitored under the microscope to examine their morphology. 
Spontaneous differentiating colonies appear with irregular borders. Although some 
degree of differentiated cells (<10% of the plate) is expected, higher frequency leads 
to poor HPC production. Differentiating cells can be marked and aspirated from the 
well to purify the colonies. Confluent SFCi55 cells (~60%) are passaged with 
mechanical dissociation, using the STEMPRO EZPassage disposable passaging tool 
(Thermofisher Scientific, cat#23181010), according to the manufacturer protocol. 
SFCi55 that reach 80% of confluency were transferred into low-profile 6-multiwell 
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plate to be differentiated into haematopoietic progenitors. Embryoid bodies formation 
(from day 0 to day 4) occurred in EB media containing 50ug/ml BMP4, 50ug/ml 
VEGF and 20ug/ml SCF (all from Peprotech). From day 5 to day 11 the differentiation 
media was supplemented with VEGF (15ng/ml), Dkk (150ng/ml), IL-6 (10ng/ul), 
IGF-1 (25ng/ml), IL-11 (5ng/ml), SCF (50ng/ml), EPO (2U/ml final), TPO (30ng/ml), 
IL-3 (30ng/ml) and Flt-3L (10ng/ml) as indicated in (Kennedy, Awong et al. 2012). 
At day 11 of differentiation EBs were harvested and dissociated using TryplE (Gibco, 
cat#12563011), resuspended in FACS buffer (10% FBS/PBS) and stained with 
hCD38-PE and hCD34-eFluor450 (see Table 3.1). The i55GPR56CA iPSC line was 
established targeting the AAVS1 locus. Left & Right Zinc Fingers nucleases were 
kindly provided by Forrester laboratory. 1x10^6 SFCi55 were transfected with Left 
(1ug) & Right (1ug) Zinc Fingers plasmids together with AAVS1-TetOn-hGPR56CA 
plasmid (3ug) using Nucleofector Technology (Lonza), according to the manufacturer 
protocol. Transfected (positive) clones were selected adding 400ug/ml Neomycin into 
the maintenance medium and kept in culture for 10 days. Single clones were picked, 
expanded in a 6-multiwell plate and screened using 2 set of primers (see Table 3.2). 
The i55GPR56CA line was validated adding doxycycline (1 mg/ml, according to the 
Tet-ON 3G inducible expression Systems User Manual manufacturer protocol, 
Clonotech) to the medium and GPR56 transcript levels were quantified using RT-
qPCR assay (see Table 3.2). Karyotype on the newly generated i55GPR56CA iPSC 
line needs to be performed to exclude genomic anomalies.     
2.7 Zebrafish embryos 
The in vivo experiments were performed by Dr. Emma de Pater at the Erasmus 
Medical Center, Dept of Hematology, Rotterdam NL. Zebrafish (Danio rerio) 
embryos were raised at 28.5oC (Solaimani Kartalaei, Yamada-Inagawa et al. 2015). 
Heterozygous - 6.0itga2b:EGFP zebrafish (CD41-GFP) (Lin, Traver et al. 2005); -
0.8flt1:RFP (Flt1:RFP) (Bussmann, Bos et al. 2010) were maintained by crosses with 
WT zebrafish and embryos imaged with Leica SP5 confocal microscope. All mRNA 
in vitro expression constructs were generated by amplification of appropriate cDNA 
with specific primers (see Table 3.2) and resulting PCR products were cloned into p-
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GEM-T vector, sequence verified and mRNA was generated using Ambion sp6 or T7 
mRNA generation kit. 
2.8 Morpholino and mRNA injections 
The experiments were performed by Dr. Emma de Pater at the Erasmus Medical 
Center, Dept of Hematology, Rotterdam NL. Antisense morpholino against the splice 
site of the second intron (Table 3.2; Gene Tools) was dissolved in MQ at a 
concentration of 1 mM (1 nl MO was injected in a 1/5 concentration in 0.1M KCl and 
phenol red). For mRNA rescue experiments, 1nl of 50 ng/l mRNA and 200M was 
injected. 
2.9 Statistical Analysis 
All graphs were generated using GraphPad Prism. A one-way ANOVA corrected by 
Bonferroni’s test was used to compare more than 2 groups, whereas the Student t test 
was used when the groups to compare were only two. Significance was defined as 
*p0.05, **p0.01, ***p0.001. 
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Table 2.1 Antibodies  
   
Antigen Fluorophore Clone Company Isotype
CD3 PE 17A2 BioLegend Rat IgG2b, k
CD3 PerCP-Cy5.5 145-2C11 eBioscience
Armenian 
hamster/IgG
B220 PE RA3-6B2 BD Biosciences Rat IgG2a, k
Ly6C/Ly6G (Gr1) PE RB6-8C5 BD Biosciences Rat IgG2b, k
Ly6C/Ly6G (Gr1) APC-Cy7 RB6-8C5 BD Biosciences Rat IgG2b, κ
Ter119 PE TER-119 BD Biosciences Rat WI
Ter119 BV421 TER-119 BD Biosciences Rat WI
CD11b PE M1/70 eBioscience Rat IgG2b, κ
CD11b BV605 M1/70 BioLegend Rat IgG2b, κ
CD48 AF700 HM48-1 BioLegend
Armenian 
hamster/IgG
NK1.1 AF700 PK136 BioLegend Mouse IgG2a, k
Sca1 PE-Cy7 D7 eBioscience Rat IgG2a, k
CD150 BV605 TC15-12F12.2 BioLegend Rat IgG2a, L
CD117 (c-Kit) BV421 2B8 BD Biosciences Rat WI
CD117 (c-Kit) APC 2B8 BD Biosciences Rat WI
CD31 BV605 390 BioLegend Rat IgG2a, k
CD41 eFluor450 MWReg30 eBioscience Rat IgG1a, k
CD45 AF700 30-F11 BioLegend Rat IgG2b, κ
CD16/32 PE 93 eBioscience Rat IgG2a, L
CD4 AF700 GK1.5 eBioscience Rat IgG2b, κ
CD8 PE-Cy5 53-6.7 BioLegend Rat IgG2a, k
CD19 BV650 6D5 BioLegend Rat
CD45.1 APC A20 BD Biosciences
Mouse A.SW 
IgG2a, κ
CD45.2 PE 104 BD Biosciences Mouse SJL IgG2a, κ
hCD38 PE HIT2 BD Pharmingen Mouse IgG1, κ
hCD34 eFluor450 4h11 eBioscience Mouse IgG1, κ
Anti-His-Tag MA1-21315 Thermofisher Mouse IgG2b
Goat anti-mouse Alexa Fluor-488 ab150113 Abcam Goat
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Table 2.2 Primer List 
 
Genotyping Forward 5’ – 3’ Reverse 5’- 3’
VEC-Cre CCCAGGCTGACC AAGCTGAG GCCTGGCGATCC CTGAACATG
GGCGACAGTTAC GCCTGGCGATCC
AGTCACAGAAGAGG CTGAACATG




Gpr56 GTGAGGTCCAGGCA TACTCG AGGAGCTCTGTGCATTGGAG
RT-qPCR
ß-actin CACCACACCTTCTTA CAATGAG GTCTCAAACATGAT CTGGGTC
Mouse Gpr56 TCTGCTCTGGCTTGTCTTC AGGTTCATGTGGACTTTGATG
Mouse Gpr97 CTGGGATATGGCTAA AGGAGAC AAGGCGAAGAAGG TCAAGTG
Human GPR56 GAAACCTCGGGACTACACCA CAGGGAGAAGTGCAGGAAGA
gRNAs
Gpr56 top CACCGtctgttgggtctggtt ccgc
Gpr56 bottom AAACgcggaaccagacccaacagaC





gpr56 coding zf ATGAACCAGAATCCA GCAAAG TTAACACTTCTCGTT AGTTTGTA
Mouse mRNA generation
gpr56 cDNA TAGGAGTATAATGGC TGTCCA CTTAGATGCGGCTG GAGGA
gpr97 cDNA CTGATGGCGACAGCCAGGA CTGCAGCCACCCATCATCA
gpr114 cDNA AATACTGGCGAGGAC ATGGA GAGCTGGGTCAGT GTGTCAT
MO sequences








SalI - cassette CAATGTCGACccaccATGGTGAGCAA CTAGGTCGACTTAGATGCGGCTGGAC
















mCherry_p2a_hGPR56  cassette 
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3 UNEXPECTED REDUNDANCIES OF GPR56 
AND GPR97 DURING HEMATOPOIETIC 
CELL DEVELOPMENT AND 
DIFFERENTIATION  
The work presented in this chapter was accepted for publication as:  
A. Maglitto, S.A. Mariani, E. de Pater, C. Rodriguez Seoane, C.S. Vink, X. Piao, M-
L Lukke and E. Dzierzak. Unexpected redundancy of Gpr56 and Gpr97 during 
hematopoietic cell development and differentiation. Blood Advances  
3.1 Introduction  
Hematopoietic stem cells (HSCs) are the rare and self-renewing cells that sustain 
lifelong blood cell production and are used clinically for reconstitution of the blood 
system in therapeutic transplantations. We identified Gpr56 as the most differentially 
expressed receptor gene during EHT in the mouse embryonic day (E) 10.5 and its 
expression localized to emerging hematopoietic cells (Solaimani Kartalaei, Yamada-
Inagawa et al. 2015). Gpr56 is an orphan receptor belonging to the adhesion G-protein 
coupled receptor family, the major class of GPCRs that mediates cell-cell and cell-
matrix interactions (Langenhan, Aust et al. 2013) and is well-conserved across 
vertebrate species. The protein contains a long external N-terminal domain, 7-
transmembrane domain and C-terminal cytoplasmic domain. Adhesion GPCRs are 
characterized by a GPCR-Autoproteolysis-INducing (GAIN) domain located between 
the N-terminus and transmembrane domain (Zhu, Luo et al. 2019). Upon ligand-
binding, an auto-proteolytic cleavage divides the protein in two non-covalently linked 
fragments and the cytoplasmic domain is thought to signal through RhoA and ROCK 
to trigger downstream cellular functions (Luo, Jeong et al. 2014, Ackerman, Garcia et 
al. 2015, Olaniru, Pingitore et al. 2018). 
 
 
40  Antonio Maglitto - January 2021 
 
Gpr56 is important in several biological development processes. For example, Gpr56 
deletion in the mouse causes a severe reduction in CNS myelination due to defective 
oligodendrocyte precursor cell maturation (Ackerman, Garcia et al. 2015, Ackerman, 
Luo et al. 2018). In some cases, its dysfunction is linked to human genetic disorders. 
Mutations in human GPR56 cause a recessive brain malformation called bilateral 
frontoparietal polymicroglia (BFPP), defective cerebral cortex and CNS 
hypomyelination (Piao, Hill et al. 2004, Cauley, Hamed et al. 2019). Interestingly, 
aberrant expression of GPR56 in leukemic stem cells (LSC) is associated with high-
risk/poor-treatment outcome in AML patients (Barjesteh van Waalwijk van Doorn-
Khosrovani, Erpelinck et al. 2003, Groschel, Sanders et al. 2014, Daria, Kirsten et al. 
2016, Pabst, Bergeron et al. 2016). Although Gpr56 is well-characterized in CNS 
development, its role in normal embryonic and adult hematopoiesis is uncertain and 
controversial. 
Key results in Gpr56 knockdown zebrafish embryos revealed a dramatic reduction in 
aortic HSPC (hematopoietic stem/progenitor cell) generation during EHT (Solaimani 
Kartalaei, Yamada-Inagawa et al. 2015). The HSPC deficiency in zebrafish Gpr56 
morphant embryos could be rescued by both zebrafish and mouse Gpr56 mRNA 
injection. Moreover, Gpr56 overexpression resulted in enhanced and ectopic 
hematopoiesis. Thus, Gpr56 is necessary and sufficient for zebrafish aortic HSPC 
development (Solaimani Kartalaei, Yamada-Inagawa et al. 2015). In contrast, although 
Gpr56 is highly expressed within mouse HSPCs (Rao, Marks-Bluth et al. 2015), one 
study in a germline Gpr56 (exon 2-3) deletion mouse model showed surprisingly small 
changes in HPC numbers and in HSC-repopulating activity (Rao, Marks-Bluth et al. 
2015) whereas another study (Saito, Kaneda et al. 2013) showed reduced self-renewal 
activity of HSC upon secondary in vivo transplantation. As some Gpr56 protein was 
detected in this mouse model (possibly because of failure to delete the S4 splice variant 
(Rao, Marks-Bluth et al. 2015)), a role for Gpr56 in normal mammalian hematopoietic 
development remains uncertain. 
In this study, we examine the functional role of Gpr56 in vivo and in vitro during mouse 
hematopoietic development. The lab generated the transgenic mice and consolidated 
the mouse ESC maintenance and differentiation protocols at the time when I started y 
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PhD. We show that in vivo transplanted Gpr56 conditional knockout mouse fetal liver 
HSCs and Gpr56 null mouse embryonic stem cell (ESC)- derived HPCs are myeloid-
lineage biased, that mouse Gpr97 mRNA can rescue HSPC generation in gpr56 
morphant zebrafish embryos, and that deletion of Gpr56 in mouse fetal liver (FL) 
HSCs and ESC-derived HPCs results in upregulated Gpr97 expression. Deletion of 
both Gpr56 and Gpr97 in mouse ESC results in almost complete loss of HPC 
production, thus revealing previously unrecognized and important redundant roles for 
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3.2 Results  
3.2.1 Phenotypic yolk sac HPCs are reduced in Gpr56 conditionally 
deleted embryos 
A conditional knockout (cKO) approach with VEC (Vascular endothelial cadherin) 
Cre:loxGpr56 was taken to specifically delete all isoforms of Gpr56 during early 
development of the hematopoietic system. Yolk sacs (YS) were isolated from 
VECCre:loxGpr56 cKO and control wild type (WT) littermates (Figure 3.1 A) at 
embryonic day (E) 9.5 (24-29 somite pairs). Sorted CD31+ YS endothelial cells were 
verified for Gpr56 deletion (Figure 3.1 B), and RT-qPCR analysis showed a marked 
decrease in relative Gpr56 mRNA in the cKO YS cells as compared to WT controls 
(Figure 3.1 C). Dr. Samanta Antonella Mariani, Chris Vink and Dr. Carmen 
Rodriguez Seoane helped dissecting the mouse embryos. Dr. Carmen Rodriguez 
Seoane performed the embryo’s genotypes. 
Examination of phenotypic hematopoietic cells by flow cytometric analysis (Figure 
3.2 A) showed that the percentage of cKit+ YS cells was significantly decreased in the 
cKO embryos compared to WT (Figure 3.2 B). Also, the percentage of erythro-
myeloid progenitors (EMPs; CD41+cKit+CD16/32+), and other progenitors 
(CD31+cKit+ and CD45+cKit+) was slightly decreased in the cKO YS compared to 
WT. The number of CFU-C/YS was significantly lower in the cKO compared to WT 
controls (Figure 3.2 C), indicating some early Gpr56-related hematopoietic 
developmental defects. Dr. Samanta Antonella Mariani performed the FACS analyses. 
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Figure 3.1 Gpr56 is down-regulated in VECCre:loxGpr56 YS-derived HPS. 
(A) Experimental setup for E9.5 yolk sac (YS) hematopoietic progenitor cell (HPC) analyses. 
(B) Genomic PCR analysis verifying Gpr56 deletion in CD31+ E9.5 YS cells (single embryos) 
from VECCre:loxGpr56 cKO as compared to control WT CD31+ yolk sac cells. (C) Relative 
expression of Gpr56 in wild type (WT) and VECCre:loxGpr56 conditional knockout (cKO) 
E9.5 YS cells normalized to -actin by qRT-PCR analysis (n=2). Dr. Samanta Antonella 
Mariani, Chris Vink and Dr. Carmen Rodriguez Seoane helped dissecting the mouse embryos. 
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Figure 3.2 Gpr56 deficiency affects early hematopoietic development in VEC-Cre mouse 
embryos. 
(A) Flow cytometric gating parameters for SSC-A, cKit, CD45, CD41 and CD16/32 cells from 
Gpr56 in wild type (WT) and VECCre:loxGpr56 cKO E9.5 YS cells. (B) Percentages of cKit+, 
CD41+cKit+CD16/32+ (EMP=erythro-myeloid progenitor), CD31+cKit+ and CD45+ckit+ cells 
in WT and cKO E9.5 yolk sacs (n=6). Mean±SEM are shown. (C) Number of colony forming 
units (CFU) per WT and cKO E9.5 YS (n=3, 3 wild types and 3 cKO embryos from 2 different 
litters in 2 different days). Distinct colony types are indicated. CFU-GEMM=granulocyte, 
erythroid, macrophage, megakaryocyte; - GM=granulocyte, macrophage; -M=macrophage; 
G=granulocyte; BFU-E=burst forming unit-erythroid. Mean±SEM are shown. Dr. Samanta 
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3.2.2 HPC and HSC function is largely unaffected in E13.5 Gpr56 
cKO fetal liver 
To examine whether Gpr56 loss affects definitive hematopoietic progenitor cells 
(HPCs) and/or HSCs, E13.5 VAVCre:loxGpr56 cKO embryos were generated and 
LSK- SLAM fetal liver (FL) cells isolated (Figure 3.3 A and B). RT-qPCR analysis 
verified reduced levels of Gpr56 transcripts in the cKO cells as compared to WT 
controls (Figure 3.3 C). No differences in the number of LSK-SLAM per E13.5 FL 
(Figure 3.3 D) were found and HPC in vitro analyses showed no significant changes 
in CFU-C/100 LSK-SLAM cKO as compared to WT cells (Figure 3.3 E). When CFU 
colonies obtained from the cKO cells were tested by DNA PCR for the Gpr56 gene, 
all (100%) of 14 colonies examined revealed that both alleles of Gpr56 were 
recombined (Figure 3.3 F). Thus, Gpr56 appears to be dispensable for FL HPC growth 
and function. Dr. Samanta Antonella Mariani, Chris Vink and Dr. Carmen Rodriguez 
Seoane helped dissecting and preparing the mouse embryos. Dr. Carmen Rodriguez 
Seoane performed the embryo’s genotypes. 
E13.5 FL LSK-SLAM cells were examined for HSC in vivo repopulating activity 
(Figure 3.4 A). Adult irradiated recipients (Ly5.1) injected with one FL LSK-SLAM 
cell equivalent (approximately 100 HSCs) of VAVCre:loxGpr56 cKO and WT cells 
(Ly5.2) showed no difference in the percentage of mice engrafted or peripheral blood 
(PB) donor cell chimerism at 4 and 16 weeks post-injection (Figure 3.4 B and C). Dr. 
Samanta Antonella Mariani, Chris Vink and Dr. Carmen Rodriguez Seoane helped 
dissecting and preparing the mouse embryos. Dr. Carmen Rodriguez Seoane 
performed the embryo’s genotypes. Chris Vink performed the transplantations. Dr. 
Samanta Antonella Mariani performed the FACS analyses.  
Donor cell chimerism in the bone marrow (Figure 3.5 A), spleen (Figure 3.5 B), 
thymus (Figure 3.6 A), and lymph nodes (Figure 3.6 B) of cKO recipients at 18 weeks 
post-transplantation was also equivalent to WT cell transplanted controls (Figure 3.6 
C). Dr. Samanta Antonella Mariani and Chris Vink helped harvesting the mouse 
tissues. Dr. Antonella Mariani performed the FACS analyses. 
Thus, Gpr56 appears to be dispensable for engraftment by large numbers of FL HSCs. 
 
 




Figure 3.3 Functional analyses of VAV-Cre FL Gpr56 cKO LSK-SLAM population 
(A) Experimental setup for E13.5 fetal liver (FL) HPC analyses. (B) Flow cytometry gating 
strategy to sort FL LSK-SLAM cells. (C) Relative expression of Gpr56 in WT and 
VAVCre:loxGpr56 cKO LSK-SLAM sorted E13.5 FL cells normalized to -actin by qRT-
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WT and cKO E13.5 FL (n=6). Mean±SEM are shown. (E) Number of CFU per WT and cKO 
E13.5 FL LSK=SLAM cells (n=4). Distinct colony types are indicated. Mean±SEM are 
shown. (F) Genomic PCR analysis verifying Gpr56 deletion in individual colonies (containing 
>50 cells) generated from WT control (4 CFU-C) and conditional knockout (cKO) 
VAVCre:loxGpr56 (14 CFU-C) E13.5 fetal liver cells. Dr. Samanta Antonella Mariani, Chris 
Vink and Dr. Carmen Rodriguez Seoane helped dissecting and preparing the mouse embryos. 
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Figure 3.4 Assessment of repopulation activity of transplanted FL-LSK SLAM 
population in recipient PB.  
(A) Experimental setup for in vivo transplantation of E13.5 fetal liver (FL) bulk cells and 
limiting dilutions of sorted LSK-SLAM cells (B) Representative gating strategy to assess the 
frequency of the donor-derived blood cells in recipient PB. Live blood cells (Hoechst-) were 
analysed for CD45.2 (donor) and CD45.1 (recipient) cell surface markers. (C) Peripheral 
blood (PB) analysis at week 4 and 16 post-transplant. Dr. Samanta Antonella Mariani, Chris 
Vink and Dr. Carmen Rodriguez Seoane helped dissecting and preparing the mouse embryos. 
Dr. Carmen Rodriguez Seoane performed the embryo’s genotypes. Chris Vink performed cell 
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Figure 3.5 Repopulation activity of transplanted FL-LSK SLAM population in other 
organs.  
Representative flow cytometry gating strategy to assess the frequency of the donor-derived 
blood cells in the bone marrow (A) and the spleen (B) of recipient mice. Live blood cells 
(Hoechst-) were resolved for CD45.2 (donor) and CD45.1 (recipient) cell surface markers. Dr. 
Samanta Antonella Mariani and Chris Vink helped harvesting the mouse tissues. Dr. Antonella 




























Figure 3.6 Repopulation activity of transplanted FL-LSK SLAM population in other 
organs.  
Representative flow cytometry gating strategy to assess the frequency of the donor-derived 
blood cells in the thymus (A) and the lymph nodes (B) of recipient mice. Live blood cells 
(Hoechst-) were resolved for CD45.2 (donor) and CD45.1 (recipient) cell surface markers. (C) 
Hematopoietic tissues at week 18 post-transplant. Analysis is by Ly5.1/Ly5.2 flow cytometry. 
Mean±SEM are shown. n=6 per group. BM=bone marrow; Sp=spleen; Thy=thymus; 
A
B
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LN=lymph nodes. Dr. Samanta Antonella Mariani and Chris Vink helped harvesting the 
mouse tissues. Dr. Antonella Mariani the FACS analyses. 
 
3.2.3 Clonal in vivo transplantation reveals a role for Gpr56 in self-
renewal and maintaining balanced and lymphoid-biased fetal 
liver HSCs 
To understand if Gpr56 affects HSC quality and/or function in a clonal in vivo 
transplantation scenario, 3, 10 and 30 LSK-SLAM FL cells (Ly5.2) from E13.5 
VAVCre:loxGpr56 embryos and WT littermates were injected into irradiated adult 
recipient mice (Ly5.1). Engraftment level of ≥5% donor-derived cells was used as the 
criterion for reconstitution. Injection of 3 LSK-SLAM cells from cKO and WT FLs 
failed to reconstitute. Injection of 10 or 30 LSK-SLAM FL WT cells (black squares) 
led to long-term (23 week) reconstitution in 75% (12 of 16) of recipients, whereas only 
50% (8 of 16) of recipients receiving 10 or 30 cKO cells (white squares) showed 
reconstitution (Figure 3.7 and 3.8). Dr. Samanta Antonella Mariani and Chris Vink 
helped performing FACS analyses.  
At both 16 and 23 weeks post-injection of 30 cells, significant decreases were found 
in the average percentage donor chimerism in the PB of cKO recipients as compared 
to WT (Figure 3.8). Similar to the PB, the percentage donor cell chimerism was 
decreased in the bone marrow (BM) (Figure 3.9 A), spleen (Sp) (Figure 3.9 B), lymph 
nodes (LN) (Figure 3.10 A) and thymus (Thy) (Figure 3.10 B) of these recipients 
(Figure 3.10 C), thus confirming HSC dysfunction. Gpr56 downregulated expression 
was verified in CD45.2+ LSK cells isolated from the PB of these cKO transplanted 
animals (Figure 3.11 A). Dr. Samanta Antonella Mariani, Chris Vink helped 
performing FACS analyses. 
To further examine qualitative effects of Gpr56 deletion on FL HSC reconstitution, 
the donor-derived lymphoid-myeloid ratio was examined in the PB of the cKO and 
WT E13.5 LSK-SLAM FL reconstituted recipients at 23 weeks post-injection (Figure 
3.11 B). Lineage output was determined by B plus T lymphoid cell percentages to 
granulocyte plus macrophage percentages (B+Tvalue/G+Mvalue), with ratios of >10, 10-
3 and 3-0 considered lymphoid-biased, balanced or myeloid-biased respectively 
 
 
52  Antonio Maglitto - January 2021 
 
(Sieburg, Cho et al. 2006). Flow cytometry with markers for myeloid (granulocytes 
and macrophages, G-M) and lymphoid (B and T cell, B-T) lineages showed lymphoid-
biased and balanced lineage output in the PB of the 12 recipients injected with WT 
HSCs, whereas PB of the 10 recipients of cKO HSC clones yielded myeloid-bias and 
balanced lineage output, and only 2 with lymphoid-bias (Figure 3.11 C). Examination 
of BM cell lineage representation showed a similar myeloid-bias by the cKO cell 
recipients: WT recipients showed all three outputs whereas cKO recipients showed 
only lymphoid- and myeloid-biased outputs (Figure 3.11 D and E). Secondary 
transplantations were performed with BM Ly5.2 cells from several of the primary 
recipients (Figure 3.11 F) to examine HSC self-renewal. None of the 12 recipients of 
cKO cells were repopulated, whereas 4 out of 12 recipients of WT cells showed PB 
chimerism from 2.5-15.3%. Dr. Samanta Antonella Mariani performed the FACS 
analyses. Chris Vink performed the transplantations.  
Together, these data suggest that Gpr56 maintains the in vivo quality of HSCs, 
preserving HSC self-renewal and lineage (balanced, lymphoid-biased) output. 
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Figure 3.7 Flow cytometry strategy to assess the engraftment potential of clonal 
transplanted FL LSK-SLAM donor cells.  
Representative gating strategy to assess the engraftment of FL-derived WT (A) and VAV-Cre 
(B) LSK-SLAM population in the PB of recipient mice. Live blood cells (Hoechst-) were 
analysed for CD45.2 (donor) and CD45.1 (recipient) cell surface markers. Dr. Samanta 
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Figure 3.8 Engraftment potential of Gpr56 cKO VAV-Cre clonal FL-LSK-SLAM donor-
cells. 
Percentage of donor cell engraftment of individual adult irradiated recipient mice as measured 
by Ly5.1/Ly5.2 flow cytometry of peripheral blood at 4, 16 and 23 weeks post- injection of 1, 
3 and 10 LSK-SLAM E13.5 FL cells. Wild type controls (WT=black) and VAVCre:loxGpr56 
knockout (cKO=white). n=8 per group. Horizontal line at 5% indicates cutoff for 
reconstitution. Horizontal lines indicate average percentage engraftment. Circled individual 
symbols indicate mice used for secondary transplantations. *p0.05; **p0.01. Dr. Samanta 
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Figure 3.9 Repopulation activity of clonal transplanted FL-LSK SLAM population in 
different organs.  
Representative flow cytometry gating strategy to assess the frequency of the donor-derived 
blood cells in the bone marrow (A) and the spleen (B) of recipient mice. Live blood cells 
(Hoechst-) were resolved for CD45.2 (donor) and CD45.1 (recipient) cell surface markers. Dr. 
Samanta Antonella Mariani and Chris Vink helped harvesting the tissues and performing the 
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Figure 3.10 Repopulation activity of clonal transplanted FL-LSK SLAM population in 
different organs. 
Representative gating strategy to assess the engraftment of FL-derived WT (A) and VAV-Cre 
(B) LSK-SLAM population in the PB of recipient mice. Live blood cells (Hoechst-) were 
analysed for CD45.2 (donor) and CD45.1 (recipient) cell surface markers. Dr. Samanta 
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Figure 3.11 Blood lineage analyses of Gpr56 cKO FL-HSCs 
(A) RT-qPCR relative expression of Gpr56 normalized to b-actin in LSK BM cells from 
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Mean±SEM are shown. (B) Percentage of lymphoid and myeloid cell contribution in PB of 22 
individual adult irradiated recipient mice as measured by flow cytometry of peripheral blood 
at 23 weeks post-injection of 10 and 30 LSK-SLAM WT control and VAVCre:loxGpr56 cKO 
E13.5 FL cells. Ly=lymphoid bias; B=balanced; My=myeloid bias. >87% B-T=Ly; 75- 87% 
B-T=B; <75% B-T=My. (C) Percentage of lymphoid, balanced and myeloid biased recipients 
in the cohort of 12 WT and 10 cKO FL LSK-SLAM cell transplant adult irradiated mice in 
Figure 4.4 B. ( (D) Percentage of BM lymphoid, balanced and myeloid biased recipients in the 
cohort of 7 WT and 6 cKO FL LSK-SLAM cell transplanted adult irradiated mice. (E) 
Percentage of lymphoid and myeloid cell contribution in bone marrow (BM) of 13 individual 
adult irradiated recipient mice as measured by flow cytometry of peripheral blood at 23 weeks 
post-injection of 10 and 30 LSK-SLAM WT control (n=7) and VAVCre:loxGpr56 cKO E13.5 
FL cells (n=7). Ly=lymphoid bias; B=balanced; My=myeloid bias. >87% B-T=Ly; 75-87% 
B-T=B; <75% B-T=My.(F) Donor cell-derived chimerism of PB of secondary recipient mice 
at 4, 16 and 23 weeks post-transplantation of bone marrow LSK cells from primary recipients 
of WT and VAVCre:loxGpr56 cKO sorted E13.5 FL cells. Percentage of CD45.2+ donor cells 
in PB is shown. Horizontal lines indicate average engraftment percentage. WT=black; 
cKO=white. n=4 per group. Dr. Samanta Antonella Mariani performed the FACS analyses. 
Chris Vink performed the transplantations.  
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4 GPR56 IS EXPRESSED IN ESC-DERIVED 
HEMATOPOIETIC PROGENITOR CELLS 
The work presented in this chapter was accepted for publication as:  
A. Maglitto, S.A. Mariani, E. de Pater, C. Rodriguez Seoane, C.S. Vink, X. Piao, M-
L Lukke and E. Dzierzak. Unexpected redundancy of Gpr56 and Gpr97 during 
hematopoietic cell development and differentiation. Blood Advances. 
 
To further examine the role of Gpr56 during hematopoietic development and lineage 
differentiation, we took advantage of our unique Gata2Venus (G2V) mouse reporter 
ESC line (Kaimakis, de Pater et al. 2016) which, upon in vitro differentiation, 
facilitates the isolation of large numbers HSPCs for molecular and functional analyses 
(Kaimakis, de Pater et al. 2016, Kauts, Rodriguez-Seoane et al. 2017). We previously 
found that only the Venus-expressing (V+) cell fraction of G2V ESC hematopoietic 
differentiation cultures contains hematopoietic potential. G2V ESCs were 
differentiated towards the hematopoietic lineage, harvested at several time points and 
tested for Gpr56 mRNA and protein expression (Figure 4.1 A). RT-qPCR analysis on 
cells from unsorted day (d) 0, 6, 10 and 12 differentiation cultures showed significant 
increases in Gpr56 transcript levels (Figure 4.1 B). When V+ and V- cell fractions of 
G2V ESC differentiation cultures were sorted (Figure 4.1 C and D), Gpr56 expression 
significantly increased in the V+ cells, reaching a maximum threshold at d10 and 12 
(Figure 4.1 E). The low level of Gpr56 expression found in non-hematopoietic V- 
cells was expected (Ackerman, Garcia et al. 2015). Western blotting of whole cell 
extracts from unsorted differentiated G2V ESC showed Gpr56 protein expression at 
d12 compared to d0 (Figure 4.1 F, left). Moreover, Gpr56 protein expression at d12 
of G2V ESC hematopoietic differentiation was much higher in the V+ fraction as 
compared to the V- fraction (Figure 4.1 F, right). Dr. Mari-Liis Lukke performed the 
western blotting analyses. Members of the QMRI FACS Facility helped on setting the 
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FACS strategy. Thus, the G2V ESC line is a suitable platform to examine the role of 
Gpr56 during in vitro hematopoietic differentiation. 
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Figure 4.1 Gpr56 is expressed during ESC hematopoietic differentiation. 
(A) ESC differentiation culture methodology. Mouse Gata2Venus (mG2V) ESC (wild type 
(WT) and 56KO were differentiated in hematopoietic factor-containing medium for 12 days and 
unsorted/sorted Venus+ (V+) and Venus- (V-) cells were examined for Gpr56 mRNA (RT-
qPCR) and Gpr56 protein (Western blot; WB) expression. (B) Time course RT-qPCR analysis 
of relative Gpr56 expression (normalized to −actin) in unsorted G2V ESC hematopoietic 
differentiation cultures. (C) Example of the gating strategy used to enrich V+ and V- fractions. 
Forward scatter (FSC), side scatter (SSC), Venus, and Venus minus autofluorescence plots are 
shown. Forward scatter (FSC), side scatter (SSC), Venus, and Venus minus autofluorescence 
plots are shown in upper panels. After gating on live cells, the Venus+ cells are plotted against 
a dump neighbor channel (B525-Venus vs B670) to exclude auto-fluorescent cells. Only the 
cells positive in the B525 channel and not in the B670 channel are considered Venus+. WT 
cells are used as control to set the gates. Fluorescent minus one (FMO) controls for cKit, 
CD16/32, CD41, CD45 antibodies in lower panels. (D) Fluorescent minus-one (FMOs) 
controls for cKit, CD16/32, CD41 and CD45 antibodies (E) Time course qRT-PCR analysis 
of relative Gpr56 expression (normalized to -actin) in Venus-sorted G2V ESC hematopoietic 
differentiation cultures. (F) Western blot analysis of Gpr56 protein expression in day 0 and 
day12 unsorted G2V ESC hematopoietic differentiation cultures (left panel) and day 12 Venus 
sorted G2V ESC hematopoietic differentiation cultures (right panel), with −actin as protein 
normalization control. The two bands correspond to different Gpr56 forms: native (upper, 
75kDa) and cleaved activated (lower, 62kDa) receptor. Gpr56 has a self-proteolytic domain 
that cleaves the N-terminal ligand binding domain in the presence of ligand, thus decreasing 
the size of the active receptor. The bulk population does not show the double band as the 
majority of the cells express Gpr56 in the native state (not active). When we enrich for the 
Venus+ HPC population, we observe the second lower band, presumably indicating cleaved 
receptor, n=2. Dr. Mari-Liis Lukke performed the western blotting analyses. Members of the 
QMRI FACS Facility helped on setting the FACS strategy.   
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4.1.1 Gpr56 knockout affects hematopoietic output during ESC 
differentiation 
To test if Gpr56 affects ESC hematopoietic differentiation, Gpr56 knockout G2V ESC 
lines (56KO) were generated by CRISPR/Cas9 gene editing. Gpr56 is located on mouse 
chromosome 8, has 14 exons and a coding sequence of 2064 base pairs (Figure 4.2). 
Guide RNA (gRNA) to exon 2 (common to all transcript variants) were cloned into 
pSP-Cas9-2A-GFP and transfected into G2V ESCs (Figure 4.3 A). At 48 hours post 
transfection, ~10% of G2V ESCs were GFP+ (Figure 4.3 B & C). Single viable GFP+ 
cells were expanded on MEFs and clones established. Two undifferentiated GFP+ ESC 
clones, #5 and #21, were examined by Western blot (Figure 4.3 D) and showed a 
complete lack of Gpr56 protein as compared to wild type (WT; #1 and #2) 
undifferentiated G2V ESC clones. RT-qPCR analysis revealed a total absence of 
Gpr56 transcripts in clone #5 (Figure 4.3 E) and #21 (Figure 4.3 F) following d6, 10 
and 12 of in vitro differentiation as compared to WT differentiated ESC, thus 
confirming the successful knockout of Gpr56. However, karyotype on G2V.56ko ESC 
lines (#5 and #21) remains to be assessed to exclude genomic anomalies.  Dr. Mari-
Liis Lukke performed the wester blotting analyses. 
Flow cytometry for HPC frequencies (McGrath, Frame et al. 2015) and CFU-C 
analyses were performed on cells from d6 (primitive HPCs)  (Figure 4.4 A, B, C) and 
d10 (EMPs) (Figure 4.5 A, B, C, D) differentiated 56KO and WT ESC cultures. After 
gating out autofluorescent cells, the percentage of V+ cells in the d6 and d10 56KO (#5 
and #21) cultures was found to be significantly increased (2.8±0.95 fold) as compared 
to the WT cultures (Figures 4.4 B and 4.5 B). At d6 a significant decrease in the 
frequency of cKit+ (#5) and cKit+CD41+ cells in the V+ fraction (#5 and #21) of 56KO 
cultures was found compared to WT (Figure 4.4 B), whereas d10 56KO ESC 
differentiation cultures showed a significant increase in cKit+ (#5 and #21; 1.3±0.2) 
and phenotypic EMP percentages (#21; 3±1.3) (Figure 4.5 B). 
When d6 56KO V+ cells were tested for HPC function, we found a 4-fold reduction in 
the number of CFU-C/104 V+ cells for both 56KO clones as compared to WT, indicating 
an almost complete absence of hematopoietic progenitor potential (Figure 4.4 C). In 
contrast, V+ cells from d10 56KO (#5 and #21) differentiation cultures revealed a trend 
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(p=0.33 and p=0.68) towards increased numbers of CFU-C/104 cells as compared to 
WT V+ cells (Figure 4.5 C). A trend in the total number of CFU-C colonies was 
observed for both clones (Figure 4.5 D). Hence, the reduction in primitive early HPCs 
and the contrasting increase in the EMPs at d10 of 56KO ESC differentiation agrees 
with in vivo Gpr56 cKO results and suggests that Gpr56 plays different roles at distinct 
development times and/or distinct emerging cells. 
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Figure 4.3 Generation of Gpr56-deleted G2V ESCs 
(A) CRISPR/Cas9 strategy showing gRNA for Gpr56 exon 2 and insertion in pSp-Cas9-2A-GFP vector 
used for transfection of G2V ESCs. (B) Flow cytometric analysis of transfected and untransfected 
control ESCs for forward (FSC) and side scatter (SSC), viability and GFP expression. (C) Fluorescence 
microscopic images of untransfected and transfected ESCs at 48 hours post- transfection (bright field 
on the left, GFP on the right). (D) Western blot analysis of Gpr56 protein expression in day 6 G2V.WT 
(clones 1 and 2) and 56KO (clones 5 and 21) ESCs, with −actin as protein normalization control. (E) 
Time course RT-qPCR analysis of relative Gpr56 expression (normalized to −actin) in unsorted 
G2V.WT and G2V. 56KO clone #5 and clone #21 (F) ESC hematopoietic differentiation cultures. d=day 
of culture harvest; n=3, Mean±SEM. *p0.05: **p0.01; ***p0.001. Dr. Mari-Liis Lukke performed 
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Figure 4.4 Output of Gpr56-KO derived hematopoietic and progenitor cells in the 
primitive wave (day 6) of in vitro hematopoiesis.  
Representative flow cytometric plots of (A) day 6 G2V.WT and G2V.56KO differentiation 
cultures showing percentages of CD16/32 and CD41 cells in cKit+ gated in Venus+. 
V+cKit+CD41+CD16/32+ = EMP (erythro-myeloid progenitors), n=3. (B) Fold change in the 
percentages (Mean±SEM) of Venus+, cKit+, cKit+CD41+ and EMPs (n=3). (C) CFU-C per 
10,000 V+ plated cells are shown. Distinct colony types are indicated by colour. n=3; 
Mean±SEM; CFU-GEMM=granulocyte, erythroid, megakaryocyte, macrophage; -
GM=granulocyte, macrophage; -G=granulocyte; M=macrophage; E=erythroid; BFU-E=burst 
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Figure 4.5 Day 10 ESC-derived hematopoietic cell production and progenitor output in 
the absence of Gpr56. 
Representative flow cytometric plots of (A) day 10 G2V.WT and G2V.56KO differentiation 
cultures showing percentages of CD16/32 and CD41 cells in cKit+, gated in Venus+. 
V+cKit+CD41+CD16/32+ = EMP (erythro-myeloid progenitors). (B) Fold change in the 
percentages (Mean±SEM) of Venus+, cKit+, cKit+CD41+ and EMPs. (C) CFU-C per 10,000 
V+ plated cells is shown. Distinct colony types are indicated by colour. n=3; Mean±SEM; 
CFU-GEMM=granulocyte, erythroid, megakaryocyte, macrophage; -GM=granulocyte, 
macrophage; -G=granulocyte; M=macrophage; E=erythroid; BFU-E=burst forming unit- 
erythroid. (D) Frequency of erythroid, myeloid and GEMM CFU types of 56KO#5 and 
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4.1.2 Gpr97 expression is upregulated in vitro and in vivo in the 
absence of Gpr56  
The discrepancy between the involvement of Gpr56 in HSPC development in zebrafish 
and mouse embryos may be a result of GPCR redundancy. In mouse, Gpr56 is 
genetically linked with Gpr97 and Gpr114 within a 122Kbp region (Gpr114 is 77Kb 
upstream and Gpr97 is 48Kb downstream). In zebrafish, gpr56 and gpr97 are both on 
chromosome 7, but distantly located at different ends of the chromosome (Figure 4.6 
A). Mouse Gpr97 and Gpr114 are highly homologous to Gpr56. As they are so closely 
linked and are co-expressed in enriched AGM HSCs 10, they may compensate for 
Gpr56 loss. 
To functionally test redundancy between Gpr56 and Gpr97, we examined whether 
mouse Gpr97 and Gpr114 mRNA, as we have shown for mouse Gpr56 (Solaimani 
Kartalaei, Yamada-Inagawa et al. 2015), could rescue hematopoietic development in 
gpr56 morphant zebrafish. Transgenic zebrafish embryos (CD41GFP and Flt1RFP 
which report HSPC generation) (Figure 4.6 B) were injected with the gpr56 
morpholino (MO) alone or in combination with zebrafish gpr56, mouse Gpr56, mouse 
Gpr97 or mouse Gpr114 mRNA (Figure 4.6 C). Double expressing CD41dimFlt1+ 
(GFP+RFP+) HSPCs in the caudal hematopoietic cell tissue (CHT) at 48 hpf were 
counted. Significant increases in the average number of HSPCs were found in gpr56 
morpholino injected with zebrafish gpr56, mouse Gpr56 and mouse Gpr97 mRNAs 
versus gpr56 morpholino controls, and HSPC numbers were equivalent to those found 
in WT controls. In contrast, mouse Gpr114 mRNA did not restore production of HSPC 
(Figure 4.6 C). These experiments were performed by Dr.Emma de Pater. Thus, in 
mouse hematopoietic development, Gpr97 but not Gpr114 may function redundantly 
in the absence of Gpr56. 
To test for possible redundancy of Gpr56 and Gpr97 during mouse embryonic 
development, we first examined whether WT G2V ESCs express Gpr97 at d0, 6, 10 
and 12 of hematopoietic differentiation. Gpr97 was not readily detected at d0 and d6, 
but high expression was found within the V+ fraction, increasing temporally to peak 
at d10 and d12 (Figure 4.7 A). Next, G2V.56KO and control ESCs were differentiated 
for 6 and 10 days and V+ cells were examined for relative Gpr97 mRNA. As compared 
 
 
70  Antonio Maglitto - January 2021 
 
to WT cells, 56KO cells showed significantly increased Gpr97 expression at d10 but 
not d6 (Figure 4.7 B), highlighting differences in possible Gpr97 redundancy in the 
absence of Gpr56 during early and late ESC hematopoietic differentiation. 
To understand if Gpr97 is highly expressed in vivo in Gpr56-cKO mouse embryos, 
Gpr97 expression levels in VECCre:loxGpr56 and VAVCre:loxGpr56 cKO embryos 
(Figure 4.6 C) were examined. RT-qPCR analyses on E9.5 YS CD31+ cells showed 
similar levels of Gpr97 in WT and Gpr56 cKO embryos. In contrast, E13.5 FL LSK-
SLAM cells showed a significant upregulated expression of Gpr97 in Gpr56 cKO 
(~1.5 fold) versus WT cells (Figure 4.6 C). Interestingly, relative Gpr97 expression 
in the donor-derived LSK sorted bone marrow cells from the recipients of 30 cKO 
E13.5 LSK-SLAM FL cells was not upregulated in the cKO compared to the WT cells 
(Figure 4.6 C). Thus, Gpr97 may function redundantly in late embryonic 
hematopoietic development both in vitro and in vivo, but not at early stages or in the 
adult.  
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Figure 4.6 In vivo experiments to assess Gpr97 redundant function in zebrafish  
(A) Schematic of the Gpr56 locus in zebrafish and mouse. Two highly homologous genes, 
Gpr114 and Gpr97 are located 5’ and 3’ respectively within the mouse Gpr56 locus. (B) 
Representative images of CD41GFPdimFlt1RFP+ cells (yellow fluorescence) in the caudal 
hematopoietic tissue (CHT) of gpr56 morpholino (MO) injected and control (WT) double 
transgenic zebrafish embryos at 48 hpf. CD41=green; Flt1= red; double positive definitive 
HSPC=yellow. (C) Rescue of HSPC production as determined by the number of 
CD41GFPdimFlt1RFP+ cells in the CHT of WT and gpr56 morphant zebrafish at 48 hpf when 
zebrafish gpr56, mouse Gpr56, mouse Gpr97 and mouse Gpr114 mRNA was injected. 
Number of experiments=2; Number of injected and analysed embryos=9, 12, 12, 7, 6, 4 
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Figure 4.7 Gpr97 upregulation in mouse ESCs and embryonic tissues 
(A) Time course RT-qPCR analysis of Gpr97 expression relative to -actin in V+ and V- 
sorted cell fractions of G2V WT ESCs from hematopoietic differentiation cultures n=3. 
Mean±SEM. (B) RT-qPCR analysis of relative Gpr97 expression (normalized to -actin) in 
sorted V+cKit+ fractions of G2V WT and 56KO day 6 and day 10 differentiated ESCs. n=3; 
*p0.05. (C) RT-qPCR analysis of relative Gpr97 expression in E9.5 VECCre:loxGpr56 cKO 
yolk sac (YS) cells (n=2), E13.5 VavCre:loxGpr56 cKO fetal liver (FL) cells (n=5) and LSK 
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4.1.3 Simultaneous deletion of both Gpr56 and Gpr97 severely 
reduces ESC-derived hematopoiesis 
To explore the functional contribution of Gpr97 during in vitro differentiation upon 
loss of Gpr56, we generated a mouse G2V.56KO97KO ESC line (56KO97KO). Guide 
RNAs (gRNA) designed to target exon 2 and exon 10 were used with CRISPR/Cas9 
methodology to knockout out all 5 potential isoforms and/or decay RNA transcripts of 
Gpr97 (Figure 4.8 A). The 56KO cell line was transfected with the gRNA plasmid 
(Figure 4.8 B) and 48 hours later cells expressing GFP (6.5%) were single cell 
deposited into multiwells (Figure 4.8 C). Of eleven clones expanded and RT-qPCR 
screened, 4 clones (B3, C10, H9, H10) showed few/no transcripts. The surveyor assay 
verified that clone B3 had a mismatch in Gpr97 (Figure 4.8 D) and sequencing 
confirmed the presence of indels in the targeted exons (for more details, see Appendix 
A) The absence of Gpr97 transcripts in undifferentiated and differentiated (d6 and 
d10) cells was confirmed by RT-qPCR (Figure 4.9 B). Hereafter, the B3 clone 
(56KO97KO) was used for phenotypic and functional studies. Karyotypes on the 
G2V.56ko97ko ESC line remains to be performed to exclude genomic anomalies.   
Hematopoietic output of d10 differentiated 56KO97KO, 56KO and WT ESC was 
performed by flow cytometry (Figure 4.9 C). The same high percentage of viable cells 
(>90%) was found for all three ESC lines (Figure 4.10 A). Whereas the increased 
percentage of the V+ population in the 56KO cells was significant and in line with our 
previous data, 56KO97KO differentiated cells showed no significant difference in the 
percentage of V+ cells as compared to WT cells. However, significant decreases in 
CD45+ hematopoietic cells and CD41+cKit+CD16/32+ (EMP) cells were observed in 
the 56KO97KO differentiated cells as compared to WT (Figure 4.10 A). This suggests 
that Gpr56 together with Gpr97 is involved in hematopoietic cell generation and/or 
differentiation of ESCs. CFU-C assays were performed to quantitate HPC production 
in cultures of d10 differentiated 56KO97KO, 56KO and WT ESCs. V+ cells were sorted, 
seeded into methylcellulose and colonies scored. In contrast to 56KO V+ cells in which 
total CFU-C frequency was similar or slightly increased to WT V+ cells, 56KO97KO V+ 
cells showed a significant large reduction in the frequency of CFU-C (Figure 4.10 B). 
Moreover, there was a significant reduction in the frequency of erythroid, myeloid and 
multipotent CFU types (Figure 4.10 C) as compared to the WT cell line. Thus, we 
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Figure 4.8 Generation of Gpr56:Gpr97 double deleted G2V ESCs. 
(A) Gpr97 gene and splice isoforms as taken from Ensembl database. (B) CRISPR/Cas9 
strategy showing gRNAs for Gpr97 exons 2 and 10 and insertion in pSp-Cas9-2A-GFP vector 
used for transfection of G2V.56KO ESCs. (C) Flow cytometric analysis of transfected and 
untransfected control ESCs for forward and side scatter, viability and GFP expression. (D) 
Surveyor assay on DNA from 4 CRISPR/Cas9 ESC clones that were negative for Gpr97 
mRNA. Clone B3 shows a mismatch in Gpr97 genomic sequence. C and G are negative and 
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Figure 4.9 In vitro functional analyses of G2V.56ko97ko ESCs 
(A) Schematic of Gpr56 and Gpr97 deletion in mouse Gpr56 locus. (B) RT-qPCR analysis of 
time course hematopoietic differentiation cultures of G2V WT and G2V. 56KO97KO ESCs. 
Relative Gpr97 expression (normalized to -actin) (n=3), Mean±SEM, ***p<0.01. (C) 
Representative flow cytometry plots for CD45+ hematopoietic cells and EMPs 
(V+CD41+cKit+CD16/32+) from day 10 differentiated G2V WT, G2V.56KO and G2V.56KO97KO 
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Figure 4.10 Decreased production of HPCs in the absence of Gpr56 and Gpr97 
(A) Percentage of viable cells and fold-change in percentages of Venus(V)+, CD45+, and EMPs 
from day10 differentiated G2V WT, G2V.56KO and G2V.56KO97KO ESC cultures. n=3. 
Mean±SEM. (B) Frequency of colony forming unit-culture cells (CFU-C) in day 10 
differentiated G2V WT, G2V.56KO and G2V.56KO97KO ESC cultures. CFU-C per 104 Venus+ 
cells is shown with colony types indicated by color. CFU-GEMM=granulocyte, erythroid, 
megakaryocyte, macrophage; GM=granulocyte, macrophage; G=granulocyte; 
M=macrophage; E=erythroid; BFU- E=burst forming unit-erythroid. n=3. Mean±SEM. (C) 
Output of CFU-C per 104 Venus+ in E according to lineage. Erythroid=CFU-E + BFU-E; 
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4.2 Discussion  
We have shown that two G-protein coupled receptors within the Gpr56 locus, the 
closely-related Gpr56 and Gpr97, function in the production and qualitative output of 
HSPCs during mouse embryonic development. While the knockout of Gpr56 alone in 
mouse ESC partially affects HPC production and biases output to the myeloid lineage, 
the double knockout of Gpr56 and Gpr97 severely reduces definitive HPC production 
and differentiation. Moreover, Gpr56 deleted fetal liver HSCs show myeloid lineage- 
bias and decreased self-renewal in vivo. Together, these data support a role for Gpr56 
in enforcing multi-lineage potential and conferring self-renewal on HSCs as they are 
generated in the embryo, reveal a time-dependent redundant function for Gpr97, and 
suggest that Gpr97 upregulation promotes the myeloid-bias of HPCs and HSCs. 
4.2.1 Gpr56 deletion provides new insights into the regulation of 
mammalian hematopoiesis 
Despite the predominant high expression of Gpr56 in quiescent adult bone marrow 
HSCs (Rao, Marks-Bluth et al. 2015), the function of this adhesion G-protein coupled 
receptor in HSCs has been a focus of controversy. Whereas a study in human leukemic 
cell lines and a germline Gpr56-/- mouse model claimed that EVI1 regulated GPR56 
maintains the HSC pool in bone marrow niches (Saito, Kaneda et al. 2013), others 
have reported that this same germline knockout mouse model was not impaired in bone 
marrow HSPC maintenance or function during homeostasis or induced myeloablative 
stress(Rao, Marks-Bluth et al. 2015). It was suggested that the discrepancy was due to 
the generation of a hypomorphic allele in vivo with low level expression of the S4 
splice variant, or to the background strain of the mice. Our finding of upregulated 
expression of Gpr56 in the emerging cells of the mouse embryo intra-aortic 
hematopoietic clusters and the impairment of aortic HSPC generation in Gpr56 
morphant zebrafish embryos (Solaimani Kartalaei, Yamada-Inagawa et al. 2015) 
encouraged us to re-examine the role of Gpr56 and ask if or how it may be functioning 
at early developmental times in the mouse. 
In our studies, Gpr56 was conditionally deleted (exon 2 floxed allele) in the HPCs and 
HSCs in the embryo with VECCre and VAVCre. E9.5 phenotypic yolk sac 
hematopoietic progenitors were quantitatively reduced, but E13.5 fetal liver LSK-
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SLAM HSC numbers were unaffected. In contrast, clonal in vivo transplantations of 
FL derived LSK-SLAM cells did reveal qualitative changes in HSCs. The absence of 
Gpr56 profoundly impairs both lineage bias and self-renewal of HSCs, thus 
implicating several distinct roles for Gpr56 at embryonic, fetal and adult stages. 
To explore this further, Gpr56-/- ESC hematopoietic differentiation cultures were 
examined. Similar to yolk sac, early day 6 differentiation cultures were decreased in 
phenotypic and functional HPCs. Day 10 differentiation cultures were slightly 
increased in phenotypic and functional HPCs, and like E13.5 fetal liver HSCs they 
showed a myeloid bias that was significant compared to control. Hence, Gpr56 likely 
affects early embryonic hematopoietic generation quantitatively, and at later 
developmental times and/or in distinct microenvironments it has a role in HSC quality. 
4.2.2 Gpr97 influences hematopoietic development in the absence of 
Gpr56 
In the context of the necessity and sufficiency of Gpr56 for HSPC generation in 
zebrafish embryos, the rather minor roles for Gpr56 in mouse hematopoietic 
development remained puzzling. If Gpr56 was essential for mouse HSPC generation, 
embryonic lethality would be expected. Instead, homozygous Gpr56 mutant adults 
could be produced, and the few hematopoietic defects found in the bone marrow were 
variable between labs (Saito, Kaneda et al. 2013, Rao, Marks-Bluth et al. 2015). Our 
rescue of Gpr56 morphant zebrafish embryo HSPC generation with mouse Gpr56 and 
Gpr97, but not Gpr114 mRNA raised the possibility of receptor redundancy in 
hematopoietic cell development and function. The location of Gpr114 and Gpr97 on 
the same locus as Gpr56 results in co-expression of these highly homologous receptors 
and the loss of genomic synteny of this region in zebrafish allowed us to identify a role 
for Gpr56. Similarly, the human GPR56 locus also contains highly homologous 
GPR114 and GPR97 genes in the same 5’ to 3’ configuration. The evolutionary 
conservation between mouse and human genes/proteins, together with the strong 
similarities in the embryonic development of adult mouse and human hematopoietic 
systems suggest a separation and overlap in the functions of Gpr56 and Gpr97 that 
could explain the minor effects seen in the Gpr56 knockout mouse models. 
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Redundancy of these two G-protein coupled receptors during mouse hematopoietic 
development is supported by our results showing Gpr97 expression in cells of E9.5 
yolk sac, E13.5 FL and adult bone marrow and also in cells of d6 and d10 ESC 
differentiation cultures. Importantly, in the absence of Gpr56, upregulated expression 
of Gpr97 was found in E13.5 FL LSK SLAM cells and d10 differentiated ESC derived 
V+cKit+ hematopoietic cells. No changes were found in Gpr97 expression in Gpr56-
/- E9.5 yolk sac and adult bone marrow. Thus, the loss of Gpr56 function in the 
embryonic definitive stages of HSPC generation is replaced by a compensatory 
expression of Gpr97.  
4.2.3 Positive role of Gpr97 or negative role of Gpr56 for myeloid 
bias? 
We observed bias toward myeloid differentiation in cells from in vitro differentiated 
Gpr56-/- ESC cultures and in vivo in the peripheral blood and bone marrow of 
recipients of Gpr56 conditional knockout E13.5 fetal liver HSCs. Previously, clonal 
lineage-biased output of HSCs has been reported to be an age-related characteristic 
(Cho, Sieburg et al. 2008, Benz, Copley et al. 2012, Geiger, de Haan et al. 2013, 
Verovskaya, Broekhuis et al. 2013). As measured by long-term in vivo clonal 
transplantation, bone marrow HSCs from young mice yield lymphoid-biased and 
balanced lymphoid-myeloid cell output in the recipients. Bone marrow from aged mice 
show a higher frequency of myeloid-biased HSC output in recipients and a decreased 
self-renewal ability in serial transplantations. The myeloid-bias of Gpr56 cKO FL 
HSCs in primary recipients together with the reduced self-renewal of HSCs as found 
in our secondary transplantations strongly support a qualitative role(s) for Gpr56 in 
HSCs and suggest that Gpr56 is responsible for maintaining the multipotency and 
robustness of HSCs throughout development. 
Indeed, these critical qualitative properties appear for the first time in midgestation 
mouse embryos when the first adult repopulating HSCs are generated in the aorta 
(Dzierzak and Speck 2008, Dzierzak and Bigas 2018). Highly upregulated Gpr56 
expression was found to be localized in the emerging intra- aortic hematopoietic 
cluster cells at E10.5/11.5 after they transition from endothelial cells (Solaimani 
Kartalaei, Yamada-Inagawa et al. 2015). Importantly, transcriptomic studies of cells 
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undergoing EHT reveal expression of Gpr97 but at lower FPKM levels relative to 
Gpr56 (Solaimani Kartalaei, Yamada-Inagawa et al. 2015). 
The relationship of distinct Gpr56 and Gpr97 expression with the distinct function in 
HSCs is difficult to ascertain. Because of the overlap in expression it remains unclear 
whether Gpr56 functions to retain multipotency or functions in a repressive capacity 
to limit myeloid bias, or whether Gpr97 (especially its upregulated expression in the 
absence of Gpr56) activates myeloid-bias. Human GPR56 was reported to negatively 
regulate the immediate effector functions of human NK cells, such as inflammatory 
cytokine production and target cell killing (Chang, Hsiao et al. 2016). Another more 
recent study reports that human polymorphonuclear cells (precursors and mature 
granulocytes) highly express GPR97, whereas monocytes and lymphocytes do not 
(Hsiao, Chu et al. 2018). These results may highlight that the balance between these 
closed-related G-protein coupled receptors in specific subsets of hematopoietic cells 
is likely to be an important factor impacting on specific cellular functions. As we have 
demonstrated here that ESC-derived hematopoiesis is severely reduced in the absence 
of both Gpr56 and Gpr97, the specific functions of these two closely-related receptors 
can only be addressed through the generation of double knockout mouse or human cell 
line models. Previously, we have tried to generate such a Gpr56-/-Gpr97-/- mouse 
model by CRISPR/Cas9 methodology but were unsuccessful, likely due to embryonic 
lethality. Future studies aim to understand the individual roles of these receptors during 
HSC development by generating an in vivo conditional knockout across both genes 
and comparing effects with single knockout and/or individual rescue of Gpr56 and 
Gpr97. 
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5 THE ROLE OF GPR56 GAIN OF FUNCTION 
IN HUMAN HEMATOPOIESIS  
5.1 Introduction  
De novo generation of adult transplantable hematopoietic stem cells (HSCs) remains 
a key approach within regenerative medicine in the management of the blood-related 
disorders. Strategies to derive HSCs from undifferentiated embryonic stem cells 
(ESCs) have been guided by the understanding of the complex networks that 
orchestrate the emergence of HSC in embryos. These networks consist of a fine 
controlled regulation of a variety of intrinsic and extrinsic signals. Their dysregulation 
impairs the onset of HSCs in embryos and correlates with leukemic stem cell (LSC) 
signature in adults. Our laboratory identified Gpr56 as novel regulator of the HSC 
onset in zebrafish and mouse (Solaimani Kartalaei, Yamada-Inagawa et al. 2015). 
Gpr56 is expressed in HSC as they are embryonically generated, and it remains 
expressed in bone marrow (BM) HSC population in adult mice. We functionally 
demonstrated that Gpr56 loss-of-function profoundly alters the HSC biology 
quantitatively and qualitatively. In zebrafish, the downregulation of Gpr56 abrogates 
the embryonic generation of HSPC population (Solaimani Kartalaei, Yamada-Inagawa 
et al. 2015), whereas in mouse we found that its absence affects the HSC quality 
(Maglitto A., Mariani S.A., 2020, under review). Upon Gpr56 deletion, murine foetal 
liver derived HSCs displayed a reduced self-renewal capacity and hold a clonal bias 
toward myeloid differentiation both in vitro and in vivo. 
Conversely, Gpr56 overexpression is frequently associated with patients affected by 
acute myeloid leukaemia (AML) (Daria, Kirsten et al. 2016, Pabst, Bergeron et al. 
2016, Jentzsch, Bill et al. 2020). These patients suffer an abnormal proliferation and 
differentiation of myeloid stem cells. Although around 60% of AML patients achieve 
a complete remission (CR) from the induction therapy (chemotherapy), the remaining 
40% relapse (De Kouchkovsky and Abdul-Hay 2016). This event is caused by few 
aggressive LSCs that resist and persist after the standard therapy. A recent study found 
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GPR56 as part of 17 biomarkers prognostic tool (LSC17) that define relapsing patients 
with aggressive LSCs (Ng, Mitchell et al. 2016). Another study demonstrated that 
GPR56 expression defines a subgroup of LSCs with higher in vivo engraftment 
potential (Pabst, Bergeron et al. 2016, Daga, Rosenberger et al. 2019). Altogether, 
these findings indicate that the controlled regulation of GPR56 plays a critical role in 
steady-state HSC biology. However, the abnormal expression of GPR56 confers 
enhanced “stemness properties” to those aggressive LSCs, so that gives them an 
unknown biological advantage to elude cancer therapies. Understanding the functional 
role of human GPR56 in normal and malignant hematopoiesis will benefit the 
development of effective strategies for de novo HSC generation and the identification 
of new intracellular targets to eradicate LSCs.  
This chapter examines the biological function of aberrant GPR56 expression in a 
human in vitro haematopoiesis differentiation model. To address this aim, I establish 
a novel human GPR56 inducible reporter iPSC line which is in vitro differentiated to 
generate hematopoietic progenitor cells (HPCs). After the activation of GPR56 
signalling pathway during the differentiation process. I evaluate the frequency of the 
in vitro derived HPCs, test their hematopoietic potential and examine characteristics 
that may be indicative of stemness. 
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5.2 Establishment of an inducible human GPR56 iPSC line  
5.2.1 Generation of the hGPR56 reporter cassettes  
To study the role of GPR56 in human haematopoiesis, I functionally test the 
hematopoietic potential of HPCs that overexpress hGPR56. To investigate the GPR56 
gain-of-function in human hematopoiesis, it is necessary to establish a stable 
engineered human PSC line that overexpresses GPR56 during in vitro hematopoietic 
differentiation. The presence of a fluorescent reporter protein facilitates the in vitro 
tracing of those cells that upregulate the ectopic GPR56. To this aim, I generate a 
custom cassette that simultaneously expresses GPR56 and mCherry reporter genes. 
GPR56 (ADGRG1) has 14 exons and is locates on chromosome 16 (16q21) of the 
human genome. The GPR56 sequence is predicted to produce a 693 amino acid protein 
characterized by different domains. The first 25 aminoacids encode a small consensus 
sequence called signal peptide (SP), which membrane proteins require to enter the 
secretory pathway. Membrane proteins that contain SP can transit through the cellular 
organelles, like ER and Golgi to undergo post-translational modifications that are 
necessary for the final maturation. Although the SP sequence is lost after protein 
maturation, its presence is required for the correct protein maturation, whereas its 
absence impairs their final destination onto the cell membrane. Upon maturation and 
insertion in the membrane, GPR56 can undergo autoproteolytic cleavage that divides 
the receptor in two different domains non-covalently associated: the extracellular N-
terminus (from 26 to 382aa) and the C-terminus (from 383 to 693aa) (Figure 5.1 A). 
To produce a continuous open-reading-frame (ORF), I generated a novel cassette 
using the full length GPR56 sequence assembled with the mCherry fluorescent 
reporter gene. Of note, several points need to be considered regarding the order of 
these two fragments. In the ideal set up, GPR56 and mCherry should be co-expressed 
at equal amount. To produce equimolar levels of a bicistronic transcript, a “self-
cleaving” 2A peptide (p2a) will be located between the two sequences. The self-
cleavage occurs between the last two residues of this 22aa-long peptide. This means 
that the sequence cloned upstream the p2a sequence will have additional residues that 
might compromise protein folding and function (Kim, Lee et al. 2011) . To avoid that 
p2a residues will affect GPR56 downstream signalling activation, the mCherry 
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sequence will be cloned upstream GPR56. The same approach is used to generate other 
2 similar mCherry-p2a-hGPR56 cassettes that will overcome some biological and 
technical limitations. The first, mCherry-p2a-his-hGPR56, will include an his-tag 
between the SP and the hGPR56 sequence. This additional sequence will facilitate the 
detection of GPR56 protein to validate the final cassette, as good reliable antibodies 
against GPR56 were not commercially available. The other cassette, mCherry-p2a-
hGPR56CA consists of a hGPR56 sequence that lacks the N-terminus end. Previous 
studies demonstrated that the deletion of the N-terminus end triggers the activation of 
GPR56 cellular signalling cascade (Paavola, Stephenson et al. 2011). This construct 
will be further used to establish the final stable hGPR56 hPSC line, where the GPR56 
downstream signalling pathway can be activated without the requirement of any 
external ligand. To summarize, three different cassettes were generated: 
- mCherry-p2a-hGPR56 full length (SP + N-terminus + C-terminus)  
- mCherry-p2a-SP-his-hGPR56 (SP + his + N-terminus + C-terminus)  
- mCherry-p2a-SP-hGPRCA (Constitutively Active form, SP + C-terminus)  
5.2.1.1 Strategy to assemble the different fragments. 
To make the custom cassettes, the Gibson assembly will be adopted as suitable cloning 
strategy to generate seamlessly ORFs. I PCR amplify hGPR56 full length, hGPR56CA, 
mCherry and SP+His sequences using a set of primers that contains at their 5’ends a 
short (22nt) sequence shared with the adjacent fragments (Figure 5.1 B and C). The 
resulting PCR amplicons were eluted and purified from the agarose gel and the 
adjacent fragments were ligated together using the Gibson reaction mix to generate the 
desired ORF cassettes (Figure 5.1 D, primers listed in Table 2.2)  
Afterwards, each resulting cassette was cloned into pcDNA3.1 mammalian expression 
vector, whose backbone contains all the mammalian gene expression regulatory 
elements and the bacterial ampicillin resistance. The ampicillin resistance will select 
those bacteria that have been positively transfected with the custom plasmids.  
Figures 5.1 E, F, G show the bacteria clones that have been PCR screened for each 
single cassette. The bands indicate those clones that are positive for the custom 
cassettes. Of note, the efficiency of the Gibson cloning varies according to the number 
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and the length of the fragments that have been assembled. The plasmids isolated from 
positive bacteria were sequenced to ensure that no mutations occurred within the ORF 
cassettes (see Appendix B). I select the correct cassettes to validate in vitro the 
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Figure 5.1 Generation of three mCherry-GPR56 cassettes.  
(A) Protein structure of human GPR56. The different colours indicate the protein domains: N-
terminus (pink), C-terminus (blue) (B) PCR amplification of each single fragments: hGPR56 
(2082bp), hGPR56CA (950bp), mCherry_p2a (711bp) (C) PCR amplification of the SP-His 
tag fragment (110bp) (D) Schematic representation of the Gibson assembly strategy for the 
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three different cassettes: mCherry-p2a-hGR56 full length (2886bp, top), mCherry-p2a-SP-his-
hGPR56 (2928bp, middle), mCherry-p2a-SP-hGPR56CA (1815bp, bottom).. (E, F, G) 
Screening of bacteria cells transformed with the Gibson ligation products. The bands show the 
bacteria clones that are positive for (E) mCherry-p2a-hGPR56 (2886bp), (F) mCherry-p2a-
SP-his-hGPR56 (2928bp) and (G) mCherry-p2a-hGPRCA (1815bp). See Appendix B for the 
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5.2.1.2 Validation of the resulting cassettes 
After the custom cassettes have been generated and sequenced, it remains to establish 
whether mCherry and GPP56 are transcribed and whether GPR56 protein properly 
matures to be expressed in the cell surface membrane. To address these points, the 
pcDNA3.1 mCherry-p2a-his-hGPR56 is validated in vitro using 293HEK cells. Due to 
time-related and technical limitations, such as GPR56 antibody availability for protein 
detection, the mCherry-p2a-his-hGPR56 is the suitable plasmid to perform different 
in vitro assays. As this plasmid shares the same structure with the other custom 
plasmids, I am confident that conclusions made from these results could be reasonably 
extended to the other plasmids.  
293HEK cells were transfected with pcDNA3.1 mCherry-p2a-his-hGPR56 alongside 
with control conditions: 293HEK untransfected (UT) and transfected with pcDNA3.1 
empty vector (EV). 48 hours post-transfection, 293HEK cells were observed under 
fluorescent microscope and FACS analysed to estimate the frequency of mCherry 
expressing cells. Figures 5.2 A and B demonstrate that almost 80% of 293HEK cells 
transfected with mCherry-p2a-his-hGPR56 are mCherry+. RT-qPCR gene expression 
analysis demonstrates that GPR56 transcript levels in these cells is upregulated as 
compared to the control counterparts (Figure 5.2 C). At the protein level, western 
blotting analysis confirms that in mCherry-p2a-his-hGPR56 transfected cells the 
amount of GPR56 protein is higher than the controls. Finally, the immunostaining 
using an antibody against the His-tag confirms that GPR56 reaches the cell membrane. 
Indeed, Figure 5.3 shows that the majority of mCherry positive cells (red dots) express 
GPR56 (green) on their surface membrane.   
The validation of the mCherry-p2a-his-hGPR56 vector confirms that it possible to 
trace those cells that are expressing ectopic GPR56. Although only mCherry-p2a-his-
hGPR56 has been tested at the protein level, mCherry-p2a-hGPRCA was employed to 
establish the inducible engineered hPSC reporter cell line. The engineered line allows 
to examine the effect of GPR56 gain-of-function on HPCs during human in vitro 
hematopoiesis.      
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Figure 5.2 Validation of the mCherry-p2a-his-hGPR56 cassette. 
(A) Microscopy pictures of 293HEK cells transfected with an empty vector (left panel) and 
mCherry-p2a-his-hGPR56 (right panel). The red dots represent the cells that are expressing 
mCherry fluorescent protein 48 hours post transfection. Scale bar=100 um (B) The bar graph 
shows the percentage of 293HEK expressing mCherry after FACS analysis. 293HEK cells 
were transfected with mCherry-p2ac-his-hGpr56 plasmid. 48 hours post transfection, the cells 
were analysed and compared with 293HEK untransfected (UT) and transfected cells with an 
empty vector (EV) n=2. (C) Quantitative PCR analysis of hGPR56 mRNA level from 293HEK 
mCherry positive cells 48 hours post-transfection. 293HEK untransfected (UT) and 
transfected with an empty vector (EV) are used as controls. The hGpr56 expression levels 
were normalized to the β-actin reference gene. (D) Western blot of hGPR56 full-length 
(75kDa) protein on 293HEK cells untransfected and transfected with an empty vector or 
mCherry-p2a-hGPR56. β-actin was used as reference control.  
 
 
90  Antonio Maglitto - January 2021 
 
 
Figure 5.3 GPR56 is properly expressed in the cell membrane. 
(A) Immunofluorescent staining of 293HEK cells 24 hours post transfection. The cells were 
transfected with an empty vector (left panel) and with mCherry-p2a-his-hGPR56 plasmid 
(right panel). The blue dots represent the nuclei (DAPI), the red cells are expressing mCherry. 
The cells that show both red and green (his-tag) stains are those that are expressing hGPR56 
(indicated by the small white arrows) n=1. The left panel (Empty vector) shows some degree 
of green auto fluorescent in the background. Scale bar=100um (B) High magnification of 
293HEK cells transfected with mCherry-p2a-his-hGPR56 (24 hours of transfection). Blue dots 
are the nuclei (DAPI), red cells are expressing mCherry and the green stain (his-tag) shows 
GPR56 expressed around the cell membrane. n=2, scale bar=25um.  
A
B
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5.2.2 Targeting a human iPSC line with an inducible hGPR56 vector 
5.2.2.1 The Tet-On system as an eligible inducible system 
The modulation of gene expression is an experimental approach that scientists broadly 
use to study the function of relevant genes. This has been achieved using different 
conditional methods such as the Cre-Lox, the Flp-FRT, the Cre-Estrogen Receptor 
(ER) and the tetracycline-inducible (Tet) system. Whilst the Cre-Lox and the Flp-FRT 
systems alter the gene expression permanently, the Cre-ER and Tet approaches can 
reversibly manipulate the expression of a gene of interest (GOI) by the external 
administration of a drug. For this reason, Cre-ER and Tet are widely employed in 
developmental studies, where gene expression is spatial and temporal restricted. 
Although Cre-ER and Tet systems function similarly, the Tet system gives an optimal 
and rapid control of the hGPR56 expression. 
The Tet inducible system relies on a group of proteins and regulatory elements (known 
as operon Tn10) that bacteria developed to resist tetracycline. Tn10 consists of three 
elements: the tetracycline-responsive repressor protein (TetR), the operator sequences 
(TetO) and its downstream tetracycline-resistant gene (TetA). In the steady state, TetR 
is constitutively expressed and binds TetO with high affinity, repressing TetA 
expression. Conversely, the presence of tetracycline changes TetR protein 
conformation so that it dissociates the bond to TetO, inducing the expression of TetA. 
This configuration is called Tet-Off (Meier, Wray et al. 1988). In 1995 Gossen and 
colleagues modified and improved the Tet-Off system to modulate the expression of 
eukaryotic genes. They developed a novel Tet-On system, which consists of a reverse 
tetracycline-transactivator (rtTA), a GOI and TetO. The GOI is located downstream of 
a stretch of TetO repeats that are fused with a minimal eukaryotic promoter (TRE). In 
the Tet-On system, the rtTA is constitutively expressed but is unable to bind the TRE 
(Figure 5.4 A). The presence of the doxycycline (a tetracycline analogue) modifies 
rtTA conformation, allowing its binding with the TRE region, which results in the 
transcription of the GOI (Gossen, Freundlieb et al. 1995) (Figure 5.4 B). However, 
drug toxicity in the host cells remains the major drawback of the inducible systems 
(Zhou, Vink et al. 2006). In addition, conventional Tet-On systems carry rtTA, TetO 
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and GOI in different plasmids. This leads to tedious and time-consuming rounds of 
transfection, expansion and selection of positive clones.  
These limitations have been overcome using a novel modified version of the 
commercially available Tet-On3G. The new system (all-in-one-Tet-On) improves the 
sensitivity of the rtTA to lower doses of doxycycline and lacks background activity 
(Zhou, Vink et al. 2006). Importantly, it holds all the Tet-On elements in one single 
vector, optimising the time to generate a Tet-On inducible transgenic cell lines. Figure 
5.5 A illustrates the structure of the custom all-in-one-Tet-On vector (for more details, 
see Appendix C). TRE sequence locates at the 5’ end followed by the GOI, whereas 
the rtTA element is at the 3’ end followed by the EF-1a promoter, which induce its 
constitutive activation. The presence of a polyA signal at the 3’ end of rtTA avoids the 
unforeseen expression of the GOI. When doxycycline is added, rtTA increases its 
affinity for the TRE and promotes the transcription of the GOI. I will insert the newly 
formed mCherry-p2a-hGPR56/his/CA cassettes into the all-in-one-Tet-On vector to 
establish an inducible mCherry-p2a-hGPR56/his/CA knock-in vectors. To deliver 
these vectors into the human genome, it is important to develop a safe and efficient 
targeting strategy to insert them into the iPSC genome.  
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Figure 5.4 Schematic illustration of the Tet-On inducible system. 
(A) In the absence of doxycycline, the transcriptional activator (rtTA) is constitutively 
expressed but unable to bind the TetO elements. (B) The doxycycline changes the rtTA’s 




Figure 5.5 Scheme of the all-in-one-Tet-On donor vectors. 
(A) The all-in-one-Tet-ON AAVS1 donor vector (11,200bp) contains different elements: the 
Tet-On regulatory sequences (TetO, rtTA), AAVS1 homology arms (HA), neomycin and 
puromycin (not shown) resistances. The plasmid includes a SalI restriction site and two EcoRI 
sites. The SalI site will receive the newly formed mCherry-p2a_hGPR56/his/CA cassettes, 
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5.2.2.2 Strategy to integrate hGPR56 cassettes into the human genome. 
Gene editing technologies are powerful tools to study the function of a gene in vivo 
and in vitro, which include downregulation, knock-out and knock-in (Gaj, Gersbach 
et al. 2013). The latter approach consists of the integration of a transgene into a host 
genome. Historically, the insertion of a transgene into host cells was achieved using 
the physiological cell homologous recombination (HR), although this approach 
resulted time consuming and inefficient. Interestingly, scientists found that genomic 
double breaks (DSBs) activate the homology directed repair (HDR) pathway, which 
accepts homologous sequences as donor templates to repair genomic damages 
(Cannan and Pederson 2016). Molecular biologists took advantage of this system to 
increase the efficiency of the gene knock-in by co-delivering enzymes that generate 
genomic nicks (endonucleases) and donor vectors that contain host genomic 
homologous sequences, called homology arms, HAs (Moehle, Rock et al. 2007). This 
approach will be used to perform Tet-On-hGPR56 knock-in into human iPSC line. To 
generate DSBs, I use the Zinc Fingers Nucleases (ZFNs). Such ZFNs are chimeric 
nucleases resulted from the fusion of the FokI non-specific restriction endonuclease 
domain with zinc-finger DNA-binding proteins. These are 30 amino-acids long 
synthetic proteins that recognise a contiguous 18 bp DNA sequence with high 
specificity (Liu, Segal et al. 1997). The ZFNs need to be carefully designed to target 
the specific genomic location where the donor vector will be integrated. Therefore, the 
choice of the host genomic locus is crucial to guarantee the proper transgene 
expression.  
An ideal gene knock-in strategy should ensure the stable expression of the transgene 
without altering the cell physiological processes. Conventional knock-in approaches 
employed gamma-retroviral and lentiviral particles as vectors to integrate and express 
a transgene. However, the viral delivery systems present limitations that affect the 
expression of the transgene and host endogenous genes. As viral genomic integration 
occurs randomly, the transgene can dysregulate the expression of important host genes, 
causing the activation of oncogenes or the mutation of oncosuppressors. The alteration 
of these two classes of genes frequently leads to an aberrant cell clonal expansion or 
malignant transformation. Another limitation is the silencing of the transgene. This 
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event takes place when the transgene integrates within an intronic or heterochromatic 
portion of the genome. Moreover, changes in the chromatin conformation often occur 
during in vitro differentiation protocols. During the differentiation process, PSCs 
undergo progressive and continuous variations in their epigenetic architecture that 
might cause the silencing of the transgene. To avoid these drawbacks, studies 
identified three suitable human loci to accommodate the integration of the transgene: 
the chemokine receptor 5 (CCR5), the human ortholog of the mouse Rosa26 locus and 
the adeno-associated virus site 1 (AAVS1) located in chromosome 19. The AAVS1 is 
a well-studied locus that is ubiquitously expressed in multiple cell types. A transgene 
delivered in this genomic locus preserves a good expression without interfering with 
host regulatory elements (Lombardo, Cesana et al. 2011). For this reason, the AAVS1 
locus is consider the safe acceptor locus that will ensure a robust transgene expression 
during  iPSC in vitro differentiation (Papapetrou and Schambach 2016). 
To integrate the Tet-On-hGPR56 cassettes into the AAVS1 locus, the donor plasmid 
brings two externals left (HLA, 528bp) and right (HRA, 762bp) homology arms that 
enable the homologous recombination with the locus (Figure 5.5 A) (Yang, Ma et al. 
2017). Moreover, to increase the targeting efficiency, ZNFs have been specifically 
designed to perform genomic nicks in the AAVS1 locus. The simultaneous transfection 
of the AAVS1-specific ZFNs with the AAVS1-Tet-On-hGPR56 donor vector ensures 
the site-specific integration of the hGPR56 transgene in the human AAVS1 safe 




96  Antonio Maglitto - January 2021 
 
5.2.2.3 Generation of the AAVS1-Tet-On-hGPR56 donor vectors 
Molecular cloning approaches were used to generate three different AAVS1-Tet-On 
donor vectors: AAVS1-Tet-On-hGPR56, AAVS1-Tet-On-his-hGPR56 and AAVS1-Tet-
On-hGPR56CA. Firstly, the AAVS1-TetOn plasmid was digested with SalI and EcoRI. 
EcoRI has been used to perform a diagnostic digestion of the donor backbone, while 
SalI enzyme cuts out the sequence previously cloned into the AAVS1-Tet-On 
backbone. The resulting agarose gel restriction fragment separation confirmed the in 
silico prediction of the AAVS1-Tet-On plasmid map. EcoRI generated a band of ~1450 
bp (Figure 5.6 A), whereas SalI gave three fragments (Figure 5.6 B). The middle band 
(~9kbp) corresponds to the linearized backbone, the bottom band (~7kb) represents 
the insert that was previously cloned into the donor backbone, whilst the upper band 
likely resembles the uncut plasmid. The linearized AAVS1-Tet-On plasmid (middle 
band) was purified from the agarose gel and stored for further application. 
To prepare the hGPR56 transgenes, I PCR-amplified the mChery-p2a-hGPR56 
(3230bp), mCherry-p2a-hGPR56CA (2159bp) and mCherry-p2a-his-hGPR56 
(3254bp) cassettes that have been previously cloned into pcDNA3.1 plasmid (Figure 
5.6 C). Each cassette includes also the polyA sequences at their 3’ends. The polyA 
signal is fundamental to ensure the correct mRNA nuclear export, stabilisation and 
translation. The set of primers designed for the cassettes contains the SalI RE 
sequences at their 5’ and 3’ ends. This will be useful to generate the sticky overhangs 
required for the ligation of the cassettes into the AAVS1-Tet-ON backbone. The three 
different resulting amplicons were resolved on agarose gel, eluted and digested with 
SalI. Then, each cassette was ligated into SalI digested AAVS1-Tet-On backbones and 
transformed into E.coli competent cells. Viable bacteria colonies were PCR screened 
using a set of primers that amplify the entire mCherry-p2a-hGPR56 cassette (Figure 
5.7 A). The positive bands indicate the bacteria that have the correct plasmid. Among 
all the bacteria screened, the agarose gels show that only 6, 1, and 2 bacteria have 
successfully ligated AAVS1-Tet-On-mCherry-p2a-hGPR56, AAVS1-Tet-On-mCherry-
p2a-his-hGPR56 and AAVS1-Tet-On-mCherry-p2a-hGPR56CA cassettes respectively 
(Figure 5.7 B, C, D). However, the use of a single restriction enzyme does not ensure 
the correct orientation of the hGPR56 cassettes. Figures 5.8 A and B summarise the 
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strategy adopted to establish cassette orientation. Therefore, a set of primers was 
specifically designed to establish the orientation of the cassettes in the positive 
plasmids. A forward primer anneals the 3’ end of hGPR56, while the revers is 
complementary with the rtTA sequence. The hGPR56 correct orientation produce an 
amplicon of ~2900bp (Figures 5.8 A), whereas a ~1200bp fragment indicates the 
wrong orientation (Figures 5.8 B). Correct orientations are found in donor vectors 
coming from colony #83 (mCherry-p2a-hGPR56), #16 (mCherry-p2a-his-hGPR56) 
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Figure 5.6 Preparation of the donor vector and amplicons. 
(A) Diagnostic digestion of the Tet-On-AAVS1 vector with SalI, EcoRI and uncut plasmid. 
The EcoRI digestion results in a band of 1450bp and undigested plasmid (upper band). (B) 
The SalI cut resulted in three different bands. The upper band (~20kbp) likely corresponds to 
the uncut plasmid, whereas the middle band (~10kbp) is the linearized conformation. The 
bottom band (~7kbp) correspond to the human RUNX1c gene and other regulatory sequences 
that were previously cloned into the Tet-On-AAVS1 plasmid. (C) The agarose shows the 
mCherry_p2a_hGPR56 (~3200bp), mCherry_p2a_hGPR56ca (~2100bp) and the 
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Figure 5.7 Screening of AAVS1-Tet-On-hGPR56/his/CA transformed bacteria. 
(A) Schematic representation of the PCR screening strategy. (B) The bands indicate the 
number of bacteria that ligated successfully mCherry-p2a-hGPR56 (~3200bp), (C) mCherry-
p2a-his-hGPR56 (~3200bp), (D) mCherry-p2a-hGPR56CA (~2100bp) into the AAVS1-Tet-
























Figure 5.8 Directionally screening to establish the correct cassette’s orientation. 
Different length of amplicons establishes whether the cassette is ligated in the correct (1200bp) 
(A) or wrong (2900) (B) direction. The following agarose gels show the results of the 
directional screening of positive bacteria clones for mCherry_p2a_hGPR56 (C) 
mCherry_p2a_his_hGPR56 (D) and mCherry_p2a_hGPR56ca. The bottom extra band 
represents non-specific amplicons (E) Clones #83 (C), #16 (D) and #8 & #9 (E) have the 
correct orientation of the cassettes. To ensure the correct orientation of the cassette, each 
sample was PCR amplified in duplicate using the same PCR reagents but different PCR 
polymerization times (elongation step): 1.5 minutes (loaded in the left lane) and 4 minutes 
(loaded in the right lane). The band showed in the left line confirms that the cassette has the 
correct orientation. Gene Ruler 1kb Plus (Thermo Scientific cat# 11511635) was used as DNA 
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5.2.2.4 Establishment and validation of the i55GPR56CA human iPSC line 
SFCi55 was transfected with AAVS1-Tet-On-mCherry-p2a-hGPR56CA 
(Constitutively Active form) donor vector by electroporation. To select positive 
clones, electroporated cells were cultured in maintenance medium supplemented with 
neomycin. Afterwards, 18 viable clones were picked, and PCR screened. The 
screening consists in two rounds of amplification using two different set of primers. 
The first set amplifies the mCherry-p2a-hGPR56CA cassette (1782bp), whereas the 
second, amplifies a fragment that spans the vector portion and the AAVS1 host locus 
(2045bp). This resulting amplicon confirms that the donor vector has been integrated 
correctly in the AAVS1 locus (Figure 5.10 A). The clones that show positive bands in 
both PCRs are those that have integrated correctly the AAVS1-Tet-On-mCherry-p2a-
hGPR56CA donor vector. The clones that do not show both bands simultaneously, 
most likely, have integrated the cassette in a different location of the genome. This 
random integration could cause the silencing of the transgene or alter cell functions 
leading to abnormal cellular behaviour. Of the 18 viable clones selected by neomycin, 
14 are positive for mCherry-p2a-hGPR56CA (Figure 5.10 B) Among them, 8 clones 
(clone #B, D, M, N, O, P, Q, V) resulted positive for the second PCR amplification 
(Figure 5.10 C). The PCR amplicons confirm that the AAVS1-Tet-On-mCherry-p2a-
hGPR56CA donor vector has been properly integrated into the AAVS1 locus of clones 
#B, D, M, N, O, P, Q, V. Most likely, the other bands on the bottom of the agarose gel 
are the amplification of unwanted non-specific genomic products. Among the positive 
clones, I validate clone #M and use it to perform functional hematopoietic analyses. 
From now onwards, I refer to it as i55GPR56CA. Karyotype on the newly generated 
i55GPR56CA iPSC line needs to be performed to exclude genomic anomalies. 
To validate the inducible reporter gene activation, undifferentiated and differentiating 
i55GPR56CA were tested in the presence or the absence of doxycycline. 24 hours after 
been exposed to doxycycline, undifferentiated cells activate the reporter mCherry gene 
(Figure 5.11 A and B). Similarly, day 6 (D6) differentiating i55GPR56CA embryoid 
bodies (EBs) were mCherry positive after the doxycycline has been added into the 
culture media at D4 (Figure 5.12 A). The same EBs were harvested and FACS 
analysed to evaluate the frequency of the mCherry expressing cells. Around 32% of 
single live cells are mCherry expressing (Figure 5.12 B). To assess whether mCherry+ 
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fraction expresses hGPR56CA, D6 i55GPR56CA EBs were FACS sorted into 
mCherry+ and mCherry- fractions. RT-qPCR analysis shows that hGPR56CA 
transcript is exclusively expressed by the mCherry+ as compared to mCherry- cells 
(Figure 5.12 C). The validation of the established i55GPR56CA cell line reported that, 
upon doxycycline, mCherry+ cells overexpress hGPR56CA during in vitro 
differentiation. This novel i55GPR56CA iPSC line will be used to investigate the 
hematopoietic output of HPCs after hGPR56CA overexpression. 
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Figure 5.9 Workflow to establish the i55GPR56CA iPSC line. 
(A) SFCi55 cell line has been targeted with AAVS1-TetOn-hGPR56ca. (B) The neomycin 
supplemented in the medium selects the clones that have integrated the AAVS1-TetOn-
hGPR56ca donor vector. (C) PCR screening of neomycin resistant clones to assess the proper 
integration of the AAVS1-TetOn-hGPR56ca in the AAVS1 locus. (D) The selected clone has 
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Figure 5.10 Screening of viable SFCi55-after neomycin selection 
(A) Strategy to assess the correct targeting of the AAVS1-Tet-On-hGPR56CA donor vector. 
The PCR1 amplifies the mCherry-p2a-hGPR56CA (1782bp) cassette, while PCR2 amplicon 
(2045bp) confirms that the donor vector locates in the AAVS1 locus. (B) Screening of 18 viable 
clones for the PCR1. 14 of them are positive for mCherry-p2a-hGPR56CA. (C) Screening of 
the same 18 clones for the PCR2 (Neo-AAVS1). Only 8 of them resulted positive. Correct 
bands are indicated within the red squares. 
 
  
AAVS1 TRE AAVS1p2a hGPR56CAmCherry pA NeoR
PCR2 2045 bpPCR1 1782 bp
B     C     D      E      F     G     H      I       M    N      O      P    Q      V     J       Y     X     W   wt
B     C     D      E      F     G     H      I       M    N      O      P    Q      V     J       Y     X       W     wt
PCR1 mCherry-p2a-hGPR56 (1782bp)
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Figure 5.11 Assessment of successful Tet-On-AAVS1-hGPR56CA targeting. 
Undifferentiated i55-hGPR56CA #M cells were tested in the presence (A) or absence (B) of 
doxycycline. On the left I show the bright field channels; on the right, the red channels. Each 
figure shows an example of a i55-hGPR56CA #M colony at 10x (top) and 20x (bottom) 
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Figure 5.12 Evaluation of hGPR56 transcript’s expression within the mCherry 
populations.  
To activate mCherry-hGPR56CA, doxycycline was added in the culture medium at day (d)4 
of hematopoietic differentiation. (A) Day (d)6 EBs. Bright channel on the left red channel on 
the right. Scale bar=100um (B) D6 dox-activated EBs were collected and FACS analysed. 
Viable cells were resolved for mCherry signal; mCherry+ and mCherry- population were 
FACS sorted (C) Relative mRNA expression of hGPR56 sequence in FACS-sorted mCherry+ 
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5.2.3 Functional role of GPR56 overexpression in iPSC-derived HPCs 
To investigate the hematopoietic output after the overexpression of GPR56, the 
i55GPR56CA was in vitro differentiated towards the hematopoietic lineage. Taking 
advantage of the mCherry fluorescent reporter, it is possible to trace the cells that 
overexpress GPR56 and evaluate their contribution on generating hematopoietic 
progenitor cells (HPCs). To differentiate i55GPR56CA, I developed a modified 
version of the well-established in vitro embryoid bodies (EB) based hematopoietic 
differentiation protocol, described by the Keller group (Kennedy, Awong et al. 2012). 
Similarly to the previous protocol adopted by Kennedy and colleagues, the new 
method takes advantage of the three-dimensional aggregates called embryoid bodies 
(EBs). However, it no longer necessitates to incubate human undifferentiated iPSC 
lines for 8 days under hypoxic condition to generate EBs. Along the differentiation, 
we discriminate three different stages: EB induction (EI) from day (D) 0 to D4, 
hematopoietic cell specification (HS) from D6 to D8 and hematopoietic maturation 
(HM) from D8 to D11 (Figure 5.13 A). In all these different stages, I supplemented 
the basal serum-free culture medium with different cytokine compositions. During the 
EI, the undifferentiated iPSCs were primed to induce EB formation and differentiated 
into mesodermal lineage using BMP4, SCL and VEGF cytokines. In the HS and HM 
phases, the basal medium was supplemented with different cytokine combinations that 
are required to commit the cells into the hematopoietic fate. In vitro human early HPCs 
begin to be detected by D9 and their frequency gradually increase over time to peak at 
D11. From D11 onwards, they decline and are no longer detectable by D15 (Vodyanik, 
Thomson et al. 2006, Timmermans, Velghe et al. 2009, Kennedy, Awong et al. 2012). 
The frequency of D11 i55GPR56CA derived HPCs (CD38-CD34+) was assessed in 
the presence or in the absence of doxycycline. 
To induce the constitutive GPR56 activation, doxycycline was supplemented in the 
culture medium from D4 onwards, every other day (D6, 8, 10). D11 EBs were FACS 
analysed to evaluate viable cells and the frequency of the HPCs. The analysis showed 
that there is no significant difference between the percentage of viable (Hoechst-) dox-
induced versus dox-non-induced (Figure 5.13 B).  
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To explore the functional effect of GPR56CA overexpression on HPCs, we analysed 
the frequency of D11-derived HPCs in the presence or absence of doxycycline (Figure 
5.13 C, D). GPR56CA dox-induced cells significantly increased the frequency of the 
phenotypic HPCs (CD38-CD34+) by a factor of 3.2 (1.7) as compared to the non-
induced counterpart (Figure 5.13 E). To test the hematopoietic potential, D11 CD38-
CD34+ HPCs were FACS sorted and plated into methylcellulose. CFU-C colony types 
have been scored based on their morphology after 10 days of expansion. Our 
preliminary data (n=2) demonstrated that the hematopoietic potential is selectively 
restricted to the dox-induced HPC population as compared to the CD38-CD34+ dox-
non-induced counterpart (Figure 5.13 F). Thus, induced-GPR56CA expressing cells 
showed an increase in the total number of CFUCs when compared to the dox-non-
induced (n=2). 
Afterwards, I assessed the frequency of GPR56CA expressing cells in the dox-induced 
population. Less than 40% of the viable dox-induced cells express GPR56CA (Figure 
5.14 A). However, this percentage was surprisingly sufficient to generate significant 
increases in the CD38-CD34+ population. Since the i55GPR56CA is a mixed 
population which contains up to 40% of GPR56CA expressing cells, I wanted to 
determine the origin of the CD38-CD34+ cells, whether they differentiate from 
mCherry+ or mCherry- subpopulations. I analysed the frequency of mCherry+/- cells 
within the dox-induced i55GPR56CA derived HPC population (Figure 5.14 B and C). 
Interestingly, all of single experiments revealed that ~60% of HPCs derived from the 
mCherry- fraction (Figure 5.14 D, E). I investigated whether the mCherry- HPCs 
possess an increased in vitro hematopoietic potential. The hematopoietic potential of 
D11 dox-induced mCherry+ and mCherry- derived HPCs was tested in CFU-C assay. 
Surprisingly, the CFU colony number of the dox-induced mCherry- fraction was 
higher when compared to mCherry+ counterpart (Figure 5.14 F). Altogether, these 
preliminary results lead to the hypothesis that the overexpression of GPR56CA 
increases the frequency of the in vitro derived HPCs likely by the simultaneous 
contribution of two unknown mechanisms: direct and indirect. However, few other 
hypotheses need to be considered. The simultaneous increase of mCherry- and the 
decrease of mCherry+ derived CFU-C could be caused by a toxic effect of GPR56 
overexpression or perhaps due to different protein stability between mCherry and 
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GPR56. To confirm these hypotheses, a wild-type SCFi55 (not-engineered) needs to 
be included in the experimental set-up. This control would rule out any survival effect 
induced by doxycycline when added into the culture media.  
 
Figure 5.13 In vitro functional analysis of i55GPR56CA line. 
(A) Illustration of the in vitro human haematopoietic differentiation. The protocol consists of 
three different stages: embryoid bodies induction (EI), haematopoietic specification (HS) and 
haematopoietic maturation (HM). From d4 onwards, doxycyline was added every other day. 
At d11, the embryoid bodies (EBs) were collected, dissociated and FACS-analyzed to assess 
the frequency of the haematopoietic progenitors (CD38-CD34+). (B) Percentage of viable 
cells in dox- and dox+ i55-hGPR56ca (n=12). Viable cells are defined as hoechst negative 
(Ho-). FACS analysis of day 11 haemtopoietic progenitors (HPCs) in doxycycline’s absence 
(C) or presence (D) n=5, mean +/- SEM, *p<0.05. (E) Fold change of Dox-/+ i55-hGPR56ca-
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HPCs (CD38CD34+) plated into methylcellulose, n=2, mean of no Dox CFU-G 0.5, CFU-M 
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Figure 5.14 In vitro Dox-derived HPCs arise from a non mCherry-reporter expressing 
i55GPR56CA subfraction.  
(A) Percentage of viable mCherry+ hGPR56ca expressing cells within the Dox activated i55-
hGPR56 cell line. FACS analysis of the dox- (B) and dox+ (C) HPCs. CD38-CD34+ were 
resolved for mCherry signal. (D) Percentage of mCherry+/- derived HPCs. Each column 
represents a single experiment. (E) The pie chart displays the contribution of mCherry + and 
mCherry- supopulation in generating HPCs. n=5, *p<0.05. (F) CFU-C colonies derived from 
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5.3 Discussion 
The controlled expression of Gpr56 is required for mouse embryonic HSC generation 
and for their maintenance in the adult BM (Saito, Kaneda et al. 2013, Rao, Marks-
Bluth et al. 2015, Solaimani Kartalaei, Yamada-Inagawa et al. 2015). Nevertheless, 
the effects of GPR56 aberrant expression in normal hematopoietic cells and its role in 
LSCs remain unexplored. In this chapter, I elucidated the biological effect of the 
aberrant human GPR56 expression in in vitro hematopoiesis. By generating a novel 
human inducible GPR56 reporter iPSC line (i55GPR56CA), I overexpressed GPR56 
during the hematopoietic differentiation, which resulted in enhanced HPC generation.  
To ensure GPR56 activation, I expressed a truncated GPR56 form, which is known to 
trigger the ligand-independent constitutive activation of the GPR56 downstream 
signalling pathway (Paavola, Stephenson et al. 2011). GPR56 activation remains an 
important limitation as ligands and downstream effectors are tissue dependent. Few 
studies demonstrated that GPR56 is constitutively activated in a ligand-independent 
mechanism. This has been achieved through exposing the Stachel domain by deletion 
of the n-terminal portion of the receptor (Paavola, Stephenson et al. 2011). However, 
this chapter did not provide direct evidence of the GPR56 downstream signalling 
activation. Additional experiments are required to assess the activation of downstream 
effectors, such as RhoA and ROCK phosphorylation or the activation of GPR56-
related transcription factors. 
The data highlighted that the majority of the HPCs are generated from a subset of cells 
that do not express mCherry. Few hypotheses might be formulated to explain this 
event. The first, it refers to the different protein stability between mCherry and GPR56. 
Cells that no longer express mCherry could still express constitutively active GPR56 
in the cell membrane. Or it could be possible that mCherry- HPCs benefit from a 
paracrine effect by mCheery+ dox-induced cells. This GPR56-dependent paracrine 
effect focuses attention on a novel regulatory mechanism that has not yet been 
described. Previous works conducted in melanoma reported that GPR56 
overexpression increases IL-6 secretion (Chiang, Peng et al. 2017). Another study 
demonstrated that AML blasts activate the STAT3 pro-proliferative pathway by high 
IL-6 secretion levels (Schuringa, Jonk et al. 2000). However, further experiments are 
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required to investigate the link between GPR56 dependent IL-6 secretion and the 
constitutive expression of the STAT3 pathway. 
The lower frequency of mCherry+ expressing cells is another limitation to be 
addressed. To test GPR56 overexpression, an dox-inducible GPR56 vector was 
delivered into the human AAVS1 locus. This strategy is known to overcomes the main 
drawbacks brought by lentiviral particles, such us random integration and unforeseen 
mutation of host’s important genes (Ellis 2005). Targeting the AAVS1 locus is 
supposed to avoid the transgene silencing due to epigenetic changes that occur along 
in vitro differentiation. However, recent findings reported that the AAVS1 locus 
shouldn’t be considered as an accurate safe harbour (Bhagwan, Collins et al. 2019). 
The expression of a transgene integrated in the AAVS1 locus varies between clones 
and it showed a clone-dependent degree of silencing towards hematopoietic and 
cardiomyocyte differentiation (Bhagwan, Collins et al. 2019). This drawback might 
justify the lower mCherry+ cell fraction obtained in targeted cells. It is also unknown 
whether AAVS1 engineered cells will silence the transgene overtime after several 
hematopoietic differentiations. Thus, the ectopic expression of GPR56 in the newly 
engineered cell line could be affected over time by this unforeseen clone-dependent 
silencing.  
Although some limitations remain to be addressed, collectively, the data show that the 
overexpression of GPR56CA generates higher frequency of HPC population that holds 
an enhanced hematopoietic potential. These findings raised further questions on their 
origin, whether they result from an increased number of endothelial cells that undergo 
EHT or whether GPR56 expression activates an internal feedback mechanism that 
promotes hematopoietic progenitor cell proliferation.  
To conclude, a better understanding of GPR56 in human haematopoiesis will 
contribute to develop new strategies to improve the current cancer therapies. The over-
expression and activation of GPR56 during in vitro differentiation, could contribute to 
improve well-establish protocols for de novo generation of HSC or to develop new 
therapeutic strategies to target GPR56-dependent malignant molecular pathways. 
Also, the relevant in vitro expansion of HPCs upon GPR56 over-expression might be 
used as a tool to try to expand HSCs ex vivo. However, further in vitro and in vivo 
 
 
114  Antonio Maglitto - January 2021 
 
functional examinations are required to assess the function and the long-term effects 
of these HPCs.  
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6 DISCUSSION AND FUTURE DIRECTIONS  
To date, two groups attempted to study Gpr56 loss of function in adult hematopoiesis 
(Saito, Kaneda et al. 2013; Rao, Marks-Bluth et al. 2015). However, those studies 
revealed discrepancies in their results as the mouse model adopted failed to truly 
knock-out Gpr56 (Saito, Kaneda et al. 2013; Rao, Marks-Bluth et al. 2015). This thesis 
aims to investigate the effect of Gpr56 loss-of-function and gain-of-function in the 
HSPC population using novel animal models and in vitro approaches.  
The embryonic downregulation of Gpr56 decreases YS-derived HPC frequency and 
their hematopoietic potential, whereas Gpr56 is dispensable for bulk FL-derived 
HSCs. Single cells transplantation of Gpr56 conditional knockout (cKO) FL-derived 
HSCs showed that Gpr56 is required to maintain HSC self-renewal capacity and their 
balanced hematopoietic output. Moreover, Gpr56 cKO FL-HSCs are myeloid-biased, 
as preferentially differentiate into myeloid blood cells when transplanted into recipient 
mice. These findings were confirmed also in vitro using mESC. The differentiation of 
mouse G2V.56KO ESCs generate HPCs with enhanced myeloid potential. Interestingly, 
Gpr56-cKO FL-HSCs and G2V.56KO derived HPCs upregulate another GPCR, Gpr97, 
which resides within the Gpr56 locus. Functional analyses performed in gpr56 MO 
zebrafish larvae demonstrate that Gpr97 rescues the generation of HSPCs. The 
concomitant deletion of Gpr97 and Gpr56 in mESCs impairs HPC generation, 
indicating that both receptors are required for in vitro hematopoiesis. These data 
suggest that Gpr97 might compensate for the absence of Gpr56 in FL-derived HSPCs 
and G2V.56KO HPCs, possibly driving their differentiation into myeloid cells.  
6.1 Gpr97 as putative receptor that functionally 
compensates for Gpr56 deletion. 
Similar to Gpr56, Gpr97 (Adgrg3) belongs to the adhesion GPCRs. It has a long 
extracellular domain (ECD), a stachel domain and a 7 transmembrane domain (7TM), 
which joins with an intracellular domain to trigger the signalling cascade upon receptor 
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activation (Stoveken, Hajduczok et al. 2015). The protein comparison of Gpr97 with 
Gpr56 confirmed that these domains are very similar and mostly conserved. Few 
studies have described the biological importance of Gpr97 in immune cells. Hsiao and 
colleagues provided insights into the role of aGPCRs along haematopoietic 
differentiation. The aGPCRs expression profile in human cord blood and BM 
confirmed that Gpr56 is highly expressed in HSPCs and cytotoxic lymphocytes, 
whereas Gpr97 is abundantly upregulated in polymorphonuclear cells (PMNs) (Hsiao, 
Chu et al. 2018). In PMNs, full length Gpr97 activates cAMP signalling and inhibits 
the NF-kB pathway. Like Gpr56, Gpr97 is activated by the detachment of the 
extracellular N-fragment (NTF) from the main protein. The exposition of the encrypted 
tethered agonist stachel domain, activates the receptor signalling. Thanks to in vitro 
cellular assays, the authors investigated the downstream pathways using Gpr97 full 
length and Gpr97 constitutively active form, which lack the N-terminus end. When 
compared to the full length, Gpr97 constitutively active form increased the levels of 
intracellular SRE and NF-kB, with a significant reduction of CREB (cAMP responsive 
element-binding protein) (Hsiao, Chu et al. 2018). Another study reported that Gpr97 
regulates the motility of lymphatic endothelial cell (LECs) by modulating the 
equilibrium between Cdc42 and RhoA downstream pathways (Valtcheva, Primorac et 
al. 2013). Valtcheva and colleagues showed that after Gpr97 KD, LECs activate Cdc42 
followed by cytoskeleton rearrangement that led to an improved cell migration and 
reduced cell adhesion (Valtcheva, Primorac et al. 2013). Collectively, these data 
provide preliminary evidences that Gpr97 could compensate for Gpr56 absence in 
hematopoiesis. It would be interesting to perform additional in vitro experiments with 
Gpr97 overexpression to rescue the HPC generation in G2V.56KO97KOcell line. This 
would be a key experiment to confirm Gpr97 functional compensatory mechanism in 
mouse G2V.56KO ESCs. 
6.2 To understand the molecular mechanism that regulates 
the interplay between Gpr56 and Gpr97. 
Although Gpr56 and Gpr97 share a similar structure and downstream pathway, the 
molecular mechanism that governs this potential compensatory mechanism remains to 
be explored. Future experiments are required to explain whether these two genes are 
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regulated at transcriptional and/or post-translational level. Importantly, it is unclear 
whether they share the same promoter and/or regulatory regions. As Gpr56 and Gpr97 
proteins share high homology domains and mechanism of activation, it would be 
important to ascertain whether they also share intracellular signalling pathways or 
extracellular ligands.  
Another important point to consider is the different microenvironments that HSPCs 
are exposed to at different developmental stages. The niche plays a crucial role in HSC 
commitment, specification and support during adult life (reviewed in Crisan and 
Dzierzak 2016, Gao, Xu et al. 2018). It would be interesting to understand the higher 
expression of Gpr97 in Gpr56-/- FL-HSCs but not in Gpr56-/- BM-HSCs. To 
compensate for Gpr56 downregulation,  the BM niche may provide extracellular 
signals to the HSPC population, so that they do not require to overexpress Gpr97. This 
could be interrogated by characterizing the transcriptomic profile of BM and FL 
microenvironments in Gpr56-/- mouse models. 
The most unexpected results came from the G2V.56KO97KO double knock out mES cell 
line. Very few HPCs were produced after in vitro hematopoietic differentiation. This 
prompted us to investigate the concomitant deletion of Gpr56 and Gpr97 in vivo. The 
generation of a double knock-out mouse model could not be easy to achieve, as the 
generation of a Gpr56 and Gpr97 KO germline might result in embryonic lethality. 
Currently, we are generating a floxed mouse model that would locate 2 loxP sites 
spanning Gpr56 and Gpr97 genomic sequences. To investigate the role of Gpr56 and 
Gpr97 deletion in in vivo haematopoiesis, the newly generated floxed mice will be 
crossed with the VAV- and VEC-Cre mouse models to generate Gpr56/97 conditionally 
double KO embryos. Using these mouse embryos, we will evaluate the effect of Gpr56 
and Gpr97 loss-of-function in the generation of HSCs in vivo.  
6.3 To study the reduction of self-renewal in Gpr56-/-HSCs 
The transplantation of few FL-HSCs revealed that Gpr56-/- FL-HSCs gradually reduce 
their repopulation activity after serial transplantations, which resembles the phenotype 
of aged HSCs. It would be interesting to compare the proliferation rates of young and 
aged BM derived Gpr56-/- HSCs versus WT counterparts. Moreover, it would be also 
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interesting to assess whether Gpr56-/- HSCs are unable to maintain their quiescent 
state, with enhanced differentiation rate compared to the WT. Additionally, 
transcriptomic analysis as well as ATAC sequencing may reveal important features of 
the genetic/epigenetic changes related to Gpr56 function and/or aging.  
Mobilization and homing are also important features for HSCs. As part of adhesion G-
protein coupled receptors, Gpr56 might be involved in the regulation of HSC motility. 
The lower engraftment capacity of Gpr56-/- HSCs in recipient mice might be explained 
by their reduced ability in homing or adhesion capacities after transplantation into host 
BM. Future experiments with high resolution microscopy would be beneficial to 
visualize the localisation of Gpr56-/- HSCs in the BM of recipient mice.  
6.4 To determine the signalling pathways regulated by 
Gpr56. 
Further experiments are also required to understand the signalling pathways regulated 
by the activation of Gpr56. In our preliminary experiments (data not shown), the 
addition of Col3A to the G2V mES differentiation culture media activates RhoA-
ROCK effectors. Further experiments are required to confirm these preliminary 
findings. Nevertheless, to identify pathways that are modulated by Gpr56, the mouse 
G2V cell line offers a great opportunity to profile the transcriptome of G2V.56KO as 
compared to G2V.WT.  
Gpr56 activation may be promoted also by external mechanical forces, a process that 
involves changes in the cytoskeleton architecture (Iguchi, Sakata et al. 2008, Ohashi, 
Fujiwara et al. 2017). The pathway that involves cytoskeleton changes is the Hippo 
pathway, which is regulated by cell-cell interaction, cell polarity and actin 
cytoskeleton remodelling (reviewed in (Yu and Guan 2013, Johnson and Halder 2014).  
This pathway is involved in the regulation of organ size and tumorigenesis by 
modulating cell survival, proliferation and differentiation (reviewed in Davis and 
Tapon 2019). Different GPCRs have been found to modulate Hippo pathway 
activation. Interestingly, the activation of Hippo effectors, YAP/TAZ is dependent on 
GPCRs coupled with Galpha12/13 and protein kinases Rho GTPases (Yu, Zhao et al. 
2012, Yu and Guan 2013). Investigating the relationship between Gpr56 and 
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YAP/TAZ activation during embryonic HSPC generation would represent a novel 
Gpr56-regulated downstream pathway that has not been described yet.  
6.5 GPR56 gain-of-function enhances the generation of 
HPCs. 
Although several studies characterised Gpr56 loss-of-function, few studies focused on 
investigating the Gpr56 gain-of-function in hematopoiesis (Piao, Hill et al. 2004, Ng, 
Mitchell et al. 2016, Pabst, Bergeron et al. 2016, Huang and Lin 2018). To overexpress 
GPR56 during human hematopoiesis, we established a novel inducible constitutively 
active GPR56 reporter human iPSC line and differentiated it towards HPCs. The 
engineered iPSC line ectopically expresses active GPR56 upon the addition of 
doxycycline into culture medium. Thanks to the expression of mCherry fluorescent 
reporter protein, we were able to origin-trace these HPCs. The enforced GPR56 
activation on human EBs from D4 onwards results in a 3-fold change in HPC 
expansion. HPCs mainly derived from the mCherry- fraction within doxy-activated 
cells. There are few reasons that can explain this event. It could be possible that the 
majority of the mCherrry+ cells undergo to cell death due to the cellular toxicity caused 
by the prolonged GPR56 overexpression. Another explanation might be found in the 
different protein stability between mCherry and GPR56, or it could be reasonable to 
think that some soluble factors or cytokines secreted by mCherry+ cells might activate 
some mitogenic pathway in the mCherry- cells.  
Interestingly, previous studies observed that the activation of GPR56 with CG4 mAb 
promotes the secretion of the pro-inflammatory cytokine IL-6 (Chiang, Peng et al. 
2017). IL-6 has been described to play different roles at different stages of melanoma 
development: at early stages it suppresses cell growth, whereas in later stages, it 
stimulates the expansion of  the metastasis (Hoejberg, Bastholt et al. 2012). Other 
studies reported high IL-6 expression in malignant metastatic melanoma patients who 
respond poorly to therapy (Heikkila, Ebrahim et al. 2008, Hoejberg, Bastholt et al. 
2012).  
Cytokine dysregulation is known to contribute to the pathogenesis of AML. The 
aberrant expression of pro-inflammatory cytokines has been associated with 
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proliferation, blast survival, LSC resistance to chemotherapy and long-term prognosis 
(Tsimberidou, Estey et al. 2008). Sanchez-Correa and colleagues profiled pro and 
anti/-inflammatory cytokines in the plasma of AML patients and found that increased 
IL-6 correlated with poor survival in patients with AML (Sanchez-Correa, Bergua et 
al. 2013). These findings are supported by another clinical study performed on a cohort 
of 45 paediatric patients affected by AML. The study explained the role of IL-6 BM-
derived secretion in conferring LSCs long-term survival after chemotherapy (Stevens, 
Miller et al. 2017). IL-6 has been reported as one of the ligands that activates the 
STAT3 pathway. When the pathway is active, phospho-STAT3 proteins dimerise and 
migrate into the nucleus to promote the transcription of pro-survival genes that support 
aggressive LSCs (Bromberg, Wrzeszczynska et al. 1999, Redell, Ruiz et al. 2013). IL-
6 activates STAT3 pathway in LSCs, which acquire resistance to chemotherapy and 
lead to disease progression (Stevens, Miller et al. 2017). In addition, relapsing LSCs 
maintain a higher level of IL-6-induced STAT3 activation than the same LSCs at 
diagnosis (Stevens, Ruiz et al. 2015), perhaps offering LSCs an advantage to promote 
expansion. Thus, it may be interesting to understand whether GPR56-induced IL-6 is 
the putative pro-inflammatory cytokine that promotes higher frequency of HPCs in in 
vitro hematopoiesis.  
The results presented in Chapter 5 suffers from few technical limitations. Although it 
was demonstrated by previous studies (Paavola, Stephenson et al. 2011), GPR56 
signalling activation needs to be confirmed in the newly generated i55GPR56CA iPSC 
line. Equally, an additional set of wild type iPSCs needs to be integrated in the 
experimental set up to rule out the possibility that higher frequency of HPCs are merely 
caused by the doxycycline treatment. Another limitation is the low frequency of 
mCherry+ cells. This might be caused by gene silencing, as recent studies 
demonstrated that the AAVS1 locus is not truly considered as the “safe harbour” of 
the human genome (Bhagwan, Collins et al. 2019). It could be interesting to investigate 
the effect of GPR56 overexpression in the HPC generation using a pure of GPR56-
transduced iPSC line and pulse GPR56 activation at different time-points of in vitro 
hematopoiesis.  
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6.6 To characterize the biology of GPR56-activated HPCs  
The in vitro forced overexpression of GPR56 in human hematopoiesis generated HPC 
expansion, which may resemble the phenotypic behaviour of aggressive LSCs with an 
enhanced engraftment and proliferation potential (Pabst, Bergeron et al. 2016). The 
higher frequency of GPR56-activated HPCs may be due to the contribution of two 
different biological events: an increased cellular growth and an inhibition of apoptosis. 
Further in vitro cellular assays would be required to assess the proliferation and 
apoptotic rates of doxycycline-activated cells, particularly among the mCherry+/- 
populations. Furthermore, the transplantation of doxycycline derived HPCs would 
determine the engraftment potential of GPR56-activated HPCs. To evaluate any in 
vivo leukemic behaviour of GPR56-activated cells, doxycycline activated mCherry+ 
and mCherry- fractions could be injected into immunocompromised mice and 
compared with the doxycycline negative and wild-type counterparts. 
It would be interesting to investigate the haematopoietic potential of human iPSC 
derived HPCs in the absence of GPR56. In vivo and in vitro data demonstrated that 
murine Gpr56-/- HSPCs decrease their self-renewal capacity, possess a myeloid-biased 
output and, simultaneously, upregulate Gpr97. The establishment of a novel human 
iPSC GPR56KO will provide a great opportunity to test whether these biological 
events occur in human hematopoiesis. GPR56KO derived HPCs could be examined to 
evaluate their proliferation capacity and hematopoietic bias together with gene 
expression analysis to confirm GPR97 upregulation. The deletion of GPR56 could be 
also performed on patient derived LSCs. It would be interesting to observe the effects 
of GPR56 deletion and GPR97 expression on AML blasts.  
The identification of aberrant pathways activated by GPR56 may be useful to 
distinguish healthy from malignant HSPCs. The above-mentioned studies direct our 
focus on understanding the GPR56-IL-6-STAT3 axis. Further experiments will be 
required to examine whether GPR56 activation is associated with increased IL-6 
secretion in doxycycline activated mCherry+ cells. It would be interesting to assess 
whether doxycycline activated mCherry- cells are responsive to IL-6 secretion by 
activating STAT3 pathway. These speculations would be validated using antibodies or 
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small molecules that prevent the binding between IL-6 and its receptor or inhibiting 
the activation of the STAT3 pathway.  
Finally, the ectopic and controlled expression of GPR56 may be useful as a tool to 
expand HSCs ex vivo or improve the efficiency of established protocols to generate 
HPCs in vitro. The controlled regulation of Gpr56 during in vitro differentiation might 
unlock some epigenetic patterns that could favour the generation of transplantable 
HSCs or increase HPCs yield. 
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7 CONCLUSION  
In conclusion, this thesis research provided new insights into the role of Gpr56 in 
mammalian hematopoiesis. Using in vitro and in vivo models, our study demonstrated 
that the loss of Gpr56 reduced the HSPC self-renewal and shifted their hematopoietic 
output towards myeloid cells. In these HSPCs, the reduced expression of Gpr56 is 
followed by Gpr97 upregulation. Experiments performed in zebrafish revealed that 
Gpr97 can rescue the generation of HSPC in gpr56 MO larvae. Our work tested the 
effect of GPR56 overexpression in human in vitro hematopoietic differentiation. The 
forced GPR56 expression from D4 onwards of differentiation led to an HPC 
expansion. Together, these findings advance the efficiency and promise of protocols 
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